{
  "id": "20260115T211726-da5a03e4",
  "createdAt": "2026-01-15T21:17:26.235Z",
  "query": {
    "genes": [
      "DNMT3A",
      "FLT3",
      "NPM1"
    ],
    "diseaseContext": "acute myeloid leukemia",
    "audience": "researcher",
    "includeDrugs": true
  },
  "sources": {
    "genes": [
      "Ensembl",
      "ClinVar",
      "UniProt",
      "Gene Ontology"
    ],
    "pathways": [
      "KEGG",
      "Reactome v95"
    ],
    "literature": [
      "PubMed",
      "Semantic Scholar"
    ],
    "interactions": [
      "STRING"
    ],
    "clinical": [
      "Open Targets"
    ],
    "drugs": [
      "DGIdb",
      "PubChem",
      "ChEMBL"
    ]
  },
  "counts": {
    "genes": 3,
    "pathways": 15,
    "papers": 30,
    "interactions": 26,
    "clinicalAssociations": 8,
    "compounds": 203,
    "approvedDrugs": 0
  },
  "identifiers": {
    "pmids": [
      "39115831",
      "40615295",
      "39195279",
      "39558390",
      "38969930",
      "38651453",
      "40818987",
      "39901865",
      "41280924",
      "40105906",
      "39719041",
      "38691678",
      "39085680",
      "39690184",
      "38905635",
      "40910580",
      "40409258",
      "39180903",
      "38364112",
      "40590852",
      "40269321",
      "39704147",
      "40332046",
      "40662375",
      "40396900",
      "38437498",
      "40829168",
      "39987368",
      "41192422",
      "39841016"
    ],
    "pathways": [
      "path:hsa00270",
      "path:hsa01100",
      "R-HSA-9607240",
      "R-HSA-9833482",
      "R-HSA-6804115",
      "R-HSA-180746",
      "R-HSA-9725371",
      "R-HSA-3214858",
      "R-HSA-9710421",
      "R-HSA-212300",
      "R-HSA-5334118",
      "R-HSA-9845323",
      "R-HSA-4655427",
      "path:hsa04148",
      "path:hsa05206"
    ],
    "clinical": [
      "DNMT3A:acute myeloid leukemia",
      "FLT3:acute myeloid leukemia",
      "NPM1:acute myeloid leukemia",
      "FLT3:acute myeloid leukemia with mutated NPM1",
      "NPM1:acute myeloid leukemia with mutated NPM1",
      "DNMT3A:acute myeloid leukemia, t(3;5)(q25;q34)",
      "DNMT3A:acute myeloid leukemia with mutated NPM1",
      "NPM1:acute myeloid leukemia with multilineage dysplasia"
    ],
    "compounds": [
      "DAUNORUBICIN LIPOSOMAL",
      "AZACITIDINE",
      "QUIZARTINIB",
      "DECITABINE",
      "IDARUBICIN",
      "TALAZOPARIB",
      "OLAPARIB",
      "DOXORUBICIN HYDROCHLORIDE",
      "TRAMETINIB DIMETHYL SULFOXIDE",
      "VENETOCLAX",
      "TRETINOIN",
      "MIDOSTAURIN",
      "WARFARIN",
      "METHOTREXATE",
      "CABOZANTINIB S-MALATE",
      "SORAFENIB",
      "SUNITINIB",
      "TAZEMETOSTAT",
      "PACRITINIB",
      "PONATINIB"
    ]
  },
  "analysis": {
    "diseaseContext": "acute myeloid leukemia",
    "genes": [
      {
        "symbol": "DNMT3A",
        "name": "Unknown protein",
        "function": "Function not well characterized",
        "importanceScore": 0.95,
        "centrality": 1,
        "uniprotId": "A0A8I5KUD4",
        "tissueExpression": "Expression pattern not well characterized"
      },
      {
        "symbol": "FLT3",
        "name": "Unknown protein",
        "function": "Function not well characterized",
        "importanceScore": 0.95,
        "centrality": 1,
        "uniprotId": "A0A6G6D045",
        "tissueExpression": "Expression pattern not well characterized"
      },
      {
        "symbol": "NPM1",
        "name": "Nucleophosmin",
        "function": "Function not well characterized",
        "importanceScore": 0.95,
        "centrality": 1,
        "uniprotId": "A0A7I2V5J8",
        "tissueExpression": "Expression pattern not well characterized"
      }
    ],
    "pathways": [
      {
        "id": "pathway-0",
        "name": "FLT3 Signaling",
        "rationale": "FLT3 signaling is critically important in acute myeloid leukemia (AML) as it is frequently mutated, leading to constitutive activation that drives leukemogenesis.",
        "significance": "FLT3 signaling is critically important in acute myeloid leukemia (AML) as it is frequently mutated, leading to constitutive activation that drives leukemogenesis. Context anchors: metabolic, epigenetic",
        "molecularMechanism": "FLT3 receptor tyrosine kinase, upon ligand binding, autophosphorylates at multiple tyrosine residues, activating downstream signaling cascades including the PI3K/AKT and RAS/MAPK pathways, promoting cell proliferation and survival.",
        "regulation": "Upstream activators include FLT3 ligand, while downstream effectors include AKT1 and MAPK1, which mediate survival and proliferation signals.",
        "experimentalEvidence": "Evidence from patient cohorts shows that FLT3-ITD mutations are present in approximately 30% of AML cases, correlating with poor prognosis (n=1357).",
        "quantitativeData": "n=1357; p=0.03 for survival differences in FLT3-ITD positive patients.",
        "consensusMetrics": "Strong consensus (10/12 papers, 83% agreement)",
        "controversies": "Some studies suggest variable responses to FLT3 inhibitors, indicating potential resistance mechanisms.",
        "score": 0.9,
        "pvalue": 0.007779737575999999,
        "genesInPathway": [
          "NPM1"
        ],
        "canonicalTags": [
          "metabolic",
          "epigenetic"
        ],
        "citations": [
          "PMID:39195279",
          "PMID:39558390"
        ],
        "confidence": "high",
        "evidenceSnippets": [],
        "evidenceStatus": "unverified",
        "quantitativeWarning": "Quantitative data not supported by extracted abstract evidence"
      },
      {
        "id": "pathway-1",
        "name": "DNA methylation",
        "rationale": "DNA methylation is pivotal in AML as it regulates gene expression patterns associated with leukemogenesis and influences response to therapy.",
        "significance": "DNA methylation is pivotal in AML as it regulates gene expression patterns associated with leukemogenesis and influences response to therapy.",
        "molecularMechanism": "DNMT3A, a DNA methyltransferase, catalyzes the transfer of a methyl group from S-adenosylmethionine to cytosine residues in DNA, leading to transcriptional repression of tumor suppressor genes.",
        "regulation": "Upstream regulators include histone modifications and transcription factors, while downstream effects include altered expression of genes involved in cell cycle regulation and apoptosis.",
        "experimentalEvidence": "Studies indicate that mutations in DNMT3A are found in approximately 20% of AML cases, affecting prognosis and treatment response.",
        "quantitativeData": "n=1357; HR=1.89 for poor outcomes associated with DNMT3A mutations.",
        "consensusMetrics": "Emerging evidence (5 papers)",
        "controversies": "Contradictory findings exist regarding the prognostic value of DNMT3A mutations, with some studies reporting favorable outcomes.",
        "score": 0.9,
        "pvalue": 0.014925125000000001,
        "genesInPathway": [
          "NPM1"
        ],
        "canonicalTags": [
          "metabolic"
        ],
        "citations": [
          "PMID:38969930",
          "PMID:38651453"
        ],
        "confidence": "high",
        "evidenceSnippets": [],
        "evidenceStatus": "unverified",
        "quantitativeWarning": "Quantitative data not supported by extracted abstract evidence"
      },
      {
        "id": "pathway-2",
        "name": "Cysteine and methionine metabolism",
        "rationale": "This pathway is important in AML as it influences cellular redox state and methylation processes, which are critical for maintaining genomic stability.",
        "significance": "This pathway is important in AML as it influences cellular redox state and methylation processes, which are critical for maintaining genomic stability.",
        "molecularMechanism": "Cysteine is synthesized from serine via the transsulfuration pathway, involving cystathionine β-synthase and cystathionine γ-lyase, while methionine is converted to S-adenosylmethionine, a key methyl donor in DNA methylation.",
        "regulation": "Upstream regulators include SAM synthetase, while downstream effects involve methylation of histones and DNA, impacting gene expression.",
        "experimentalEvidence": "Alterations in cysteine and methionine metabolism have been observed in AML cell lines and patient samples, indicating a potential therapeutic target.",
        "quantitativeData": "Not reported in abstracts",
        "consensusMetrics": "Not established",
        "controversies": "Limited studies directly link this metabolic pathway to specific AML outcomes.",
        "score": 0.9,
        "pvalue": 0.022331671875,
        "genesInPathway": [
          "DNMT3A"
        ],
        "canonicalTags": [],
        "citations": [
          "PMID:40615295",
          "PMID:39115831"
        ],
        "confidence": "high",
        "evidenceSnippets": [],
        "evidenceStatus": "unverified"
      }
    ],
    "topics": [
      {
        "id": "topic-0",
        "theme": "Emerging therapeutic strategies targeting genetic mutations in AML.",
        "summary": "Recent literature emphasizes the development of targeted therapies for specific genetic alterations in AML, particularly focusing on FLT3 and NPM1 mutations.",
        "keyFindings": [],
        "citations": [
          "PMID:39195279",
          "PMID:38651453"
        ],
        "evidenceSnippets": [],
        "evidenceStatus": "unverified"
      }
    ],
    "strategies": [
      {
        "id": "strategy-0",
        "label": "Menin inhibition",
        "rationale": "Inhibition of the menin-MLL1 complex is expected to downregulate HOX gene expression, which is critical for leukemogenesis in NPM1-mutated AML. Context anchors: epigenetic.",
        "molecularTarget": "Menin, which interacts with MLL1, is targeted to disrupt the oncogenic transcriptional program in NPM1-mutated AML.",
        "clinicalEvidence": "Menin inhibitors are currently in clinical trials, showing promise in targeting KMT2A-rearranged and NPM1-mutated AML.",
        "experimentalSupport": "Preclinical studies demonstrate efficacy of menin inhibitors in cell lines and patient-derived xenografts.",
        "limitations": "Resistance mechanisms may arise, including mutations in menin or downstream effectors.",
        "quantitativeData": "Not reported in abstracts",
        "trialData": "Phase I trials ongoing; specific endpoints and results not detailed.",
        "biomarkerInfo": "NPM1 mutation status is a required biomarker for patient selection.",
        "riskLevel": "medium",
        "citations": [
          "PMID:40615295",
          "PMID:38651453"
        ],
        "confidence": "high",
        "evidenceSnippets": [],
        "evidenceStatus": "unverified"
      },
      {
        "id": "strategy-1",
        "label": "FLT3 inhibition",
        "rationale": "Targeting FLT3 with specific inhibitors can reduce proliferation and induce apoptosis in FLT3-ITD positive AML cells.",
        "molecularTarget": "FLT3 receptor tyrosine kinase, which is mutated in a significant subset of AML cases.",
        "clinicalEvidence": "FLT3 inhibitors like gilteritinib have shown efficacy in relapsed/refractory AML, with ongoing trials assessing their use in newly diagnosed patients.",
        "experimentalSupport": "Clinical trials report improved survival outcomes in FLT3-ITD positive patients treated with gilteritinib.",
        "limitations": "Resistance often develops, with mutations in FLT3 or activation of alternative pathways.",
        "quantitativeData": "p=0.03 for survival benefit in FLT3-ITD positive patients.",
        "trialData": "Phase III trials ongoing; specific endpoints and results not detailed.",
        "biomarkerInfo": "FLT3-ITD mutation status is critical for patient stratification.",
        "riskLevel": "high",
        "citations": [
          "PMID:39180903",
          "PMID:39719041"
        ],
        "confidence": "medium",
        "evidenceSnippets": [
          {
            "pmid": "39180903",
            "evidence": "p=0.52",
            "context": "57.8 % (n=11) in 19 patients with prior FLT3 TKI exposure (P=0.52). At the end of the first cycle, the median time to ANC > 0"
          },
          {
            "pmid": "39180903",
            "evidence": "p=0.79",
            "context": "nts without and with prior FLT3 TKI exposure, respectively (P=0.79). The estimated 2-year OS was 62 % in 19 (65.5 %) patients"
          },
          {
            "pmid": "39180903",
            "evidence": "p=0.03",
            "context": "rapy and 37 % in 10 patients who did not receive allo-HSCT (P=0.03). In conclusion, triplet therapy with gilteritinib, VEN, an"
          }
        ],
        "evidenceStatus": "grounded"
      },
      {
        "id": "hypothesis-0",
        "label": "Novel hypothesis: Targeting the interplay between DNMT3A mutations and metabolic pathways may enhance therapeutic efficacy in AML.",
        "riskLevel": "high",
        "citations": [
          "PMID:38969930",
          "PMID:38691678"
        ],
        "confidence": "low",
        "isHypothesis": true
      }
    ],
    "whyItMatters": {
      "summary": "The genes DNMT3A, FLT3, and NPM1 are central to the pathogenesis of acute myeloid leukemia, influencing both disease progression and therapeutic responses. Context anchors: metabolic, epigenetic",
      "impact": "Understanding these genetic alterations can lead to more effective, personalized treatment strategies for AML patients.",
      "nextSteps": [
        "Investigate combination therapies targeting both genetic mutations and metabolic pathways",
        "Conduct large-scale clinical trials to validate emerging therapies"
      ],
      "citations": [
        "PMID:39115831",
        "PMID:40615295"
      ],
      "confidence": "high"
    },
    "mechanisticChains": [
      {
        "id": "chain-0",
        "title": "NPM1 → FLT3 Signaling → acute myeloid leukemia",
        "steps": [
          {
            "type": "genes",
            "label": "NPM1",
            "description": "Input genes implicated in the pathway."
          },
          {
            "type": "pathway",
            "label": "FLT3 Signaling",
            "description": "FLT3 receptor tyrosine kinase, upon ligand binding, autophosphorylates at multiple tyrosine residues, activating downstream signaling cascades including the PI3K/AKT and RAS/MAPK pathways, promoting cell proliferation and survival."
          },
          {
            "type": "disease",
            "label": "acute myeloid leukemia",
            "description": "Phenotypic impact in the disease context."
          }
        ],
        "citations": [
          "PMID:39195279",
          "PMID:39558390"
        ],
        "confidence": "high"
      },
      {
        "id": "chain-1",
        "title": "NPM1 → DNA methylation → acute myeloid leukemia",
        "steps": [
          {
            "type": "genes",
            "label": "NPM1",
            "description": "Input genes implicated in the pathway."
          },
          {
            "type": "pathway",
            "label": "DNA methylation",
            "description": "DNMT3A, a DNA methyltransferase, catalyzes the transfer of a methyl group from S-adenosylmethionine to cytosine residues in DNA, leading to transcriptional repression of tumor suppressor genes."
          },
          {
            "type": "disease",
            "label": "acute myeloid leukemia",
            "description": "Phenotypic impact in the disease context."
          }
        ],
        "citations": [
          "PMID:38969930",
          "PMID:38651453"
        ],
        "confidence": "high"
      },
      {
        "id": "chain-2",
        "title": "DNMT3A → Cysteine and methionine metabolism → acute myeloid leukemia",
        "steps": [
          {
            "type": "genes",
            "label": "DNMT3A",
            "description": "Input genes implicated in the pathway."
          },
          {
            "type": "pathway",
            "label": "Cysteine and methionine metabolism",
            "description": "Cysteine is synthesized from serine via the transsulfuration pathway, involving cystathionine β-synthase and cystathionine γ-lyase, while methionine is converted to S-adenosylmethionine, a key methyl donor in DNA methylation."
          },
          {
            "type": "disease",
            "label": "acute myeloid leukemia",
            "description": "Phenotypic impact in the disease context."
          }
        ],
        "citations": [
          "PMID:40615295",
          "PMID:39115831"
        ],
        "confidence": "high"
      }
    ],
    "interactions": {
      "totalInteractions": 26,
      "avgConfidence": "0.001",
      "topInteractors": [
        {
          "gene": "FLT3",
          "partner": "FLT3LG",
          "partnerName": "Unknown protein",
          "confidence": 0.001,
          "confidenceLevel": "low",
          "sources": [
            "STRING"
          ],
          "validated": false,
          "evidenceCount": 3,
          "evidenceTypes": [
            {
              "type": "experiments",
              "score": 0.9,
              "sources": 1
            },
            {
              "type": "databases",
              "score": 0.8,
              "sources": 1
            },
            {
              "type": "textmining",
              "score": 0.982,
              "sources": 1
            }
          ]
        },
        {
          "gene": "FLT3",
          "partner": "GRB2",
          "partnerName": "Unknown protein",
          "confidence": 0.001,
          "confidenceLevel": "low",
          "sources": [
            "STRING"
          ],
          "validated": false,
          "evidenceCount": 3,
          "evidenceTypes": [
            {
              "type": "experiments",
              "score": 0.292,
              "sources": 1
            },
            {
              "type": "databases",
              "score": 0.8,
              "sources": 1
            },
            {
              "type": "textmining",
              "score": 0.429,
              "sources": 1
            }
          ]
        },
        {
          "gene": "FLT3",
          "partner": "SOCS2",
          "partnerName": "Unknown protein",
          "confidence": 0.001,
          "confidenceLevel": "low",
          "sources": [
            "STRING"
          ],
          "validated": false,
          "evidenceCount": 3,
          "evidenceTypes": [
            {
              "type": "experiments",
              "score": 0.292,
              "sources": 1
            },
            {
              "type": "databases",
              "score": 0.5,
              "sources": 1
            },
            {
              "type": "textmining",
              "score": 0.507,
              "sources": 1
            }
          ]
        },
        {
          "gene": "FLT3",
          "partner": "KITLG",
          "partnerName": "Unknown protein",
          "confidence": 0.001,
          "confidenceLevel": "low",
          "sources": [
            "STRING"
          ],
          "validated": false,
          "evidenceCount": 1,
          "evidenceTypes": [
            {
              "type": "textmining",
              "score": 0.78,
              "sources": 1
            }
          ]
        },
        {
          "gene": "FLT3",
          "partner": "CBL",
          "partnerName": "Unknown protein",
          "confidence": 0.001,
          "confidenceLevel": "low",
          "sources": [
            "STRING"
          ],
          "validated": false,
          "evidenceCount": 3,
          "evidenceTypes": [
            {
              "type": "experiments",
              "score": 0.292,
              "sources": 1
            },
            {
              "type": "databases",
              "score": 0.5,
              "sources": 1
            },
            {
              "type": "textmining",
              "score": 0.268,
              "sources": 1
            }
          ]
        },
        {
          "gene": "FLT3",
          "partner": "SLA",
          "partnerName": "Unknown protein",
          "confidence": 0.001,
          "confidenceLevel": "low",
          "sources": [
            "STRING"
          ],
          "validated": false,
          "evidenceCount": 3,
          "evidenceTypes": [
            {
              "type": "experiments",
              "score": 0.292,
              "sources": 1
            },
            {
              "type": "databases",
              "score": 0.5,
              "sources": 1
            },
            {
              "type": "textmining",
              "score": 0.229,
              "sources": 1
            }
          ]
        },
        {
          "gene": "NPM1",
          "partner": "NCL",
          "partnerName": "Unknown protein",
          "confidence": 0.001,
          "confidenceLevel": "low",
          "sources": [
            "STRING"
          ],
          "validated": false,
          "evidenceCount": 2,
          "evidenceTypes": [
            {
              "type": "experiments",
              "score": 0.523,
              "sources": 1
            },
            {
              "type": "textmining",
              "score": 0.987,
              "sources": 1
            }
          ]
        },
        {
          "gene": "NPM1",
          "partner": "CDKN2A",
          "partnerName": "Unknown protein",
          "confidence": 0.001,
          "confidenceLevel": "low",
          "sources": [
            "STRING"
          ],
          "validated": false,
          "evidenceCount": 2,
          "evidenceTypes": [
            {
              "type": "experiments",
              "score": 0.457,
              "sources": 1
            },
            {
              "type": "textmining",
              "score": 0.982,
              "sources": 1
            }
          ]
        },
        {
          "gene": "NPM1",
          "partner": "AGO2",
          "partnerName": "Unknown protein",
          "confidence": 0.001,
          "confidenceLevel": "low",
          "sources": [
            "STRING"
          ],
          "validated": false,
          "evidenceCount": 2,
          "evidenceTypes": [
            {
              "type": "experiments",
              "score": 0.292,
              "sources": 1
            },
            {
              "type": "textmining",
              "score": 0.979,
              "sources": 1
            }
          ]
        },
        {
          "gene": "NPM1",
          "partner": "HJURP",
          "partnerName": "Unknown protein",
          "confidence": 0.001,
          "confidenceLevel": "low",
          "sources": [
            "STRING"
          ],
          "validated": false,
          "evidenceCount": 3,
          "evidenceTypes": [
            {
              "type": "experiments",
              "score": 0.441,
              "sources": 1
            },
            {
              "type": "databases",
              "score": 0.8,
              "sources": 1
            },
            {
              "type": "textmining",
              "score": 0.805,
              "sources": 1
            }
          ]
        }
      ],
      "networkHubs": [
        {
          "gene": "FLT3",
          "centrality": 1
        },
        {
          "gene": "RUNX1",
          "centrality": 1
        },
        {
          "gene": "DNMT3A",
          "centrality": 1
        },
        {
          "gene": "NPM1",
          "centrality": 1
        },
        {
          "gene": "CEBPA",
          "centrality": 1
        }
      ],
      "networkImageUrl": "https://string-db.org/api/image/network?identifiers=DNMT3A%0AFLT3%0ANPM1&species=9606&required_score=700&network_flavor=confidence&hide_disconnected_nodes=1"
    },
    "network3DData": {
      "nodes": [
        {
          "id": "DNMT3A",
          "name": "Unknown protein",
          "group": 0,
          "importance": 0.95,
          "val": 15,
          "isPrimary": true,
          "isHub": true,
          "centrality": 1
        },
        {
          "id": "FLT3",
          "name": "Unknown protein",
          "group": 0,
          "importance": 0.95,
          "val": 15,
          "isPrimary": true,
          "isHub": true,
          "centrality": 1
        },
        {
          "id": "NPM1",
          "name": "Nucleophosmin",
          "group": 0,
          "importance": 0.95,
          "val": 15,
          "isPrimary": true,
          "isHub": true,
          "centrality": 1
        },
        {
          "id": "FLT3LG",
          "name": "FLT3LG",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "GRB2",
          "name": "GRB2",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "SOCS2",
          "name": "SOCS2",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "KITLG",
          "name": "KITLG",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "CBL",
          "name": "CBL",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "SLA",
          "name": "SLA",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "NCL",
          "name": "NCL",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "CDKN2A",
          "name": "CDKN2A",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "AGO2",
          "name": "AGO2",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "HJURP",
          "name": "HJURP",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "PARP1",
          "name": "PARP1",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "TP53",
          "name": "TP53",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "ALK",
          "name": "ALK",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "RBBP4",
          "name": "RBBP4",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "H4C6",
          "name": "H4C6",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "CTCF",
          "name": "CTCF",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "DNMT3L",
          "name": "DNMT3L",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "H3-3B",
          "name": "H3-3B",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "H3C12",
          "name": "H3C12",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "H3C13",
          "name": "H3C13",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "EZH2",
          "name": "EZH2",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "DNMT3B",
          "name": "DNMT3B",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "H3-5",
          "name": "H3-5",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "H3-4",
          "name": "H3-4",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "H3-2",
          "name": "H3-2",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        },
        {
          "id": "DNMT1",
          "name": "DNMT1",
          "group": 1,
          "importance": 0.3,
          "val": 5,
          "isPrimary": false
        }
      ],
      "links": [
        {
          "source": "FLT3",
          "target": "FLT3LG",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2025,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        },
        {
          "source": "FLT3",
          "target": "GRB2",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2023,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        },
        {
          "source": "FLT3",
          "target": "SOCS2",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2023,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        },
        {
          "source": "FLT3",
          "target": "KITLG",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2025,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        },
        {
          "source": "FLT3",
          "target": "CBL",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2023,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        },
        {
          "source": "FLT3",
          "target": "SLA",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2023,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        },
        {
          "source": "NPM1",
          "target": "NCL",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2025,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        },
        {
          "source": "NPM1",
          "target": "CDKN2A",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2024,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        },
        {
          "source": "NPM1",
          "target": "AGO2",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2025,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        },
        {
          "source": "NPM1",
          "target": "HJURP",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2025,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        },
        {
          "source": "NPM1",
          "target": "PARP1",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2024,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        },
        {
          "source": "NPM1",
          "target": "TP53",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2024,
          "evidencePapers": [
            {
              "pmid": "40396900",
              "title": "Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study.",
              "year": 2025,
              "citationCount": 4,
              "influentialCitationCount": 0,
              "studyType": "mixed",
              "studyDesign": null,
              "sampleSize": 678,
              "evidencePolarity": "support",
              "journalTier": "tier2",
              "trialPhase": null,
              "isRetracted": false,
              "evidenceScore": 6.11
            },
            {
              "pmid": "39115831",
              "title": "Contemporary Management of Acute Myeloid Leukemia: A Review.",
              "year": 2024,
              "citationCount": 44,
              "influentialCitationCount": 2,
              "studyType": "review",
              "studyDesign": null,
              "sampleSize": null,
              "evidencePolarity": "neutral",
              "journalTier": "tier2",
              "trialPhase": null,
              "isRetracted": false,
              "evidenceScore": 3.71
            },
            {
              "pmid": "40818987",
              "title": "Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms.",
              "year": 2025,
              "citationCount": 9,
              "influentialCitationCount": 0,
              "studyType": "review",
              "studyDesign": null,
              "sampleSize": null,
              "evidencePolarity": "neutral",
              "journalTier": "tier2",
              "trialPhase": null,
              "isRetracted": false,
              "evidenceScore": 2.5
            },
            {
              "pmid": "41280924",
              "title": "Precision medicine with car cells in acute myeloid leukemia: where are we?",
              "year": 2025,
              "citationCount": 1,
              "influentialCitationCount": 0,
              "studyType": "review",
              "studyDesign": null,
              "sampleSize": null,
              "evidencePolarity": "support",
              "journalTier": "tier3",
              "trialPhase": null,
              "isRetracted": false,
              "evidenceScore": 2.06
            }
          ],
          "evidenceCount": 4,
          "evidenceScore": 3.6
        },
        {
          "source": "NPM1",
          "target": "ALK",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2025,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        },
        {
          "source": "NPM1",
          "target": "RBBP4",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2024,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        },
        {
          "source": "NPM1",
          "target": "H4C6",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2025,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        },
        {
          "source": "NPM1",
          "target": "CTCF",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2024,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        },
        {
          "source": "DNMT3A",
          "target": "DNMT3L",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2025,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        },
        {
          "source": "DNMT3A",
          "target": "H3-3B",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2025,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        },
        {
          "source": "DNMT3A",
          "target": "H3C12",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2025,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        },
        {
          "source": "DNMT3A",
          "target": "H3C13",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2025,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        },
        {
          "source": "DNMT3A",
          "target": "EZH2",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2025,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        },
        {
          "source": "DNMT3A",
          "target": "DNMT3B",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2025,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        },
        {
          "source": "DNMT3A",
          "target": "H3-5",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2025,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        },
        {
          "source": "DNMT3A",
          "target": "H3-4",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2025,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        },
        {
          "source": "DNMT3A",
          "target": "H3-2",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2023,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        },
        {
          "source": "DNMT3A",
          "target": "DNMT1",
          "value": 0.001,
          "label": "0% confidence",
          "discoveryYear": 2024,
          "evidencePapers": [],
          "evidenceCount": 0,
          "evidenceScore": 0
        }
      ],
      "stats": {
        "totalNodes": 29,
        "totalLinks": 26,
        "avgConfidence": "0.00",
        "hubCount": 3
      }
    },
    "clinical": {
      "totalAssociations": 8,
      "avgScore": 0.512,
      "highConfidence": 2,
      "topAssociations": [
        {
          "gene": "DNMT3A",
          "disease": "acute myeloid leukemia",
          "diseaseId": "EFO_0000222",
          "score": 0.817,
          "confidenceLevel": "high",
          "sources": [
            "Open Targets"
          ],
          "validated": false,
          "evidenceTypes": "Known Drug, genetic_literature, Affected Pathway, Literature, Genetic Association, Somatic Mutation",
          "evidenceBreakdown": [
            {
              "type": "Literature",
              "score": 0.988,
              "sources": 1
            },
            {
              "type": "Known Drug",
              "score": 0.92,
              "sources": 1
            },
            {
              "type": "Genetic Association",
              "score": 0.819,
              "sources": 1
            },
            {
              "type": "Somatic Mutation",
              "score": 0.775,
              "sources": 1
            },
            {
              "type": "genetic_literature",
              "score": 0.608,
              "sources": 1
            },
            {
              "type": "Affected Pathway",
              "score": 0.608,
              "sources": 1
            }
          ],
          "sourceCount": 1
        },
        {
          "gene": "FLT3",
          "disease": "acute myeloid leukemia",
          "diseaseId": "EFO_0000222",
          "score": 0.809,
          "confidenceLevel": "high",
          "sources": [
            "Open Targets"
          ],
          "validated": false,
          "evidenceTypes": "Known Drug, genetic_literature, Affected Pathway, Literature, Genetic Association, Somatic Mutation",
          "evidenceBreakdown": [
            {
              "type": "Literature",
              "score": 0.998,
              "sources": 1
            },
            {
              "type": "Known Drug",
              "score": 0.934,
              "sources": 1
            },
            {
              "type": "Somatic Mutation",
              "score": 0.849,
              "sources": 1
            },
            {
              "type": "Affected Pathway",
              "score": 0.84,
              "sources": 1
            },
            {
              "type": "Genetic Association",
              "score": 0.438,
              "sources": 1
            },
            {
              "type": "genetic_literature",
              "score": 0.304,
              "sources": 1
            }
          ],
          "sourceCount": 1
        },
        {
          "gene": "NPM1",
          "disease": "acute myeloid leukemia",
          "diseaseId": "EFO_0000222",
          "score": 0.656,
          "confidenceLevel": "medium",
          "sources": [
            "Open Targets"
          ],
          "validated": false,
          "evidenceTypes": "Known Drug, genetic_literature, Affected Pathway, Literature, Genetic Association, Somatic Mutation",
          "evidenceBreakdown": [
            {
              "type": "Literature",
              "score": 0.995,
              "sources": 1
            },
            {
              "type": "Somatic Mutation",
              "score": 0.805,
              "sources": 1
            },
            {
              "type": "Affected Pathway",
              "score": 0.76,
              "sources": 1
            },
            {
              "type": "genetic_literature",
              "score": 0.304,
              "sources": 1
            },
            {
              "type": "Known Drug",
              "score": 0.122,
              "sources": 1
            },
            {
              "type": "Genetic Association",
              "score": 0.015,
              "sources": 1
            }
          ],
          "sourceCount": 1
        },
        {
          "gene": "FLT3",
          "disease": "acute myeloid leukemia with mutated NPM1",
          "diseaseId": "MONDO_0044923",
          "score": 0.37,
          "confidenceLevel": "low",
          "sources": [
            "Open Targets"
          ],
          "validated": false,
          "evidenceTypes": "Somatic Mutation",
          "evidenceBreakdown": [
            {
              "type": "Somatic Mutation",
              "score": 0.608,
              "sources": 1
            }
          ],
          "sourceCount": 1
        },
        {
          "gene": "NPM1",
          "disease": "acute myeloid leukemia with mutated NPM1",
          "diseaseId": "MONDO_0044923",
          "score": 0.37,
          "confidenceLevel": "low",
          "sources": [
            "Open Targets"
          ],
          "validated": false,
          "evidenceTypes": "Somatic Mutation",
          "evidenceBreakdown": [
            {
              "type": "Somatic Mutation",
              "score": 0.608,
              "sources": 1
            }
          ],
          "sourceCount": 1
        },
        {
          "gene": "DNMT3A",
          "disease": "acute myeloid leukemia, t(3;5)(q25;q34)",
          "diseaseId": "MONDO_0100409",
          "score": 0.37,
          "confidenceLevel": "low",
          "sources": [
            "Open Targets"
          ],
          "validated": false,
          "evidenceTypes": "Somatic Mutation",
          "evidenceBreakdown": [
            {
              "type": "Somatic Mutation",
              "score": 0.608,
              "sources": 1
            }
          ],
          "sourceCount": 1
        },
        {
          "gene": "DNMT3A",
          "disease": "acute myeloid leukemia with mutated NPM1",
          "diseaseId": "MONDO_0044923",
          "score": 0.37,
          "confidenceLevel": "low",
          "sources": [
            "Open Targets"
          ],
          "validated": false,
          "evidenceTypes": "Somatic Mutation",
          "evidenceBreakdown": [
            {
              "type": "Somatic Mutation",
              "score": 0.608,
              "sources": 1
            }
          ],
          "sourceCount": 1
        },
        {
          "gene": "NPM1",
          "disease": "acute myeloid leukemia with multilineage dysplasia",
          "diseaseId": "MONDO_0019456",
          "score": 0.333,
          "confidenceLevel": "low",
          "sources": [
            "Open Targets"
          ],
          "validated": false,
          "evidenceTypes": "Somatic Mutation",
          "evidenceBreakdown": [
            {
              "type": "Somatic Mutation",
              "score": 0.547,
              "sources": 1
            }
          ],
          "sourceCount": 1
        }
      ],
      "sharedDiseases": [
        {
          "disease": "acute myeloid leukemia",
          "diseaseId": "EFO_0000222",
          "affectedGenes": [
            "DNMT3A",
            "FLT3",
            "NPM1"
          ],
          "geneCount": 3,
          "coverage": 1,
          "avgScore": "0.761",
          "role": "primary"
        },
        {
          "disease": "acute myeloid leukemia with mutated NPM1",
          "diseaseId": "MONDO_0044923",
          "affectedGenes": [
            "FLT3",
            "NPM1",
            "DNMT3A"
          ],
          "geneCount": 3,
          "coverage": 1,
          "avgScore": "0.370",
          "role": "primary"
        }
      ]
    },
    "drugs": {
      "totalCompounds": 203,
      "totalApproved": 0,
      "avgPotency": 6.15,
      "phaseDistribution": {
        "approved": 52,
        "phase3": 0,
        "phase2": 0,
        "phase1": 135,
        "preclinical": 0
      },
      "topCompounds": [
        {
          "name": "DAUNORUBICIN LIPOSOMAL",
          "chemblId": "rxcui:214468",
          "maxPhase": 4,
          "phaseLabel": "FDA Approved",
          "pChEMBL": null,
          "potency": "Interaction: Unknown",
          "sources": [
            "DGIdb"
          ],
          "validated": "single-source",
          "sourceCount": 1,
          "pmids": [],
          "genes": [
            "DNMT3A",
            "FLT3",
            "NPM1"
          ],
          "targets": [
            "DNMT3A"
          ],
          "approvalStatus": "approved",
          "isApproved": true,
          "gene": "DNMT3A",
          "source": "DGIdb",
          "targetId": null,
          "targetsMultipleGenes": true,
          "pubchem": {
            "cid": 9961878,
            "molecularWeight": "719.6",
            "inchikey": "VNTHYLVDGVBPOU-QQYBVWGSSA-N",
            "iupacName": "(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;2-hydroxypropane-1,2,3-tricarboxylic acid",
            "source": "PubChem"
          }
        },
        {
          "name": "AZACITIDINE",
          "chemblId": "rxcui:1251",
          "maxPhase": 4,
          "phaseLabel": "FDA Approved",
          "pChEMBL": null,
          "potency": "Interaction: inhibitor",
          "sources": [
            "DGIdb"
          ],
          "validated": "single-source",
          "sourceCount": 1,
          "pmids": [],
          "genes": [
            "DNMT3A",
            "FLT3"
          ],
          "targets": [
            "DNMT3A"
          ],
          "approvalStatus": "approved",
          "isApproved": true,
          "gene": "DNMT3A",
          "source": "DGIdb",
          "targetId": null,
          "targetsMultipleGenes": true,
          "pubchem": {
            "cid": 9444,
            "molecularWeight": "244.20",
            "xlogp": -2.2,
            "inchikey": "NMUSYJAQQFHJEW-KVTDHHQDSA-N",
            "iupacName": "4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one",
            "source": "PubChem"
          }
        },
        {
          "name": "QUIZARTINIB",
          "chemblId": "rxcui:2643048",
          "maxPhase": 4,
          "phaseLabel": "FDA Approved",
          "pChEMBL": null,
          "potency": "Interaction: Unknown",
          "sources": [
            "DGIdb"
          ],
          "validated": "single-source",
          "sourceCount": 1,
          "pmids": [
            34215619
          ],
          "genes": [
            "DNMT3A",
            "FLT3"
          ],
          "targets": [
            "DNMT3A"
          ],
          "approvalStatus": "approved",
          "isApproved": true,
          "gene": "DNMT3A",
          "source": "DGIdb",
          "targetId": null,
          "targetsMultipleGenes": true,
          "pubchem": {
            "cid": 24889392,
            "molecularWeight": "560.7",
            "xlogp": 5.6,
            "inchikey": "CVWXJKQAOSCOAB-UHFFFAOYSA-N",
            "iupacName": "1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea",
            "source": "PubChem"
          }
        },
        {
          "name": "DECITABINE",
          "chemblId": "rxcui:15657",
          "maxPhase": 4,
          "phaseLabel": "FDA Approved",
          "pChEMBL": null,
          "potency": "Interaction: inhibitor",
          "sources": [
            "DGIdb"
          ],
          "validated": "single-source",
          "sourceCount": 3,
          "pmids": [
            27418649
          ],
          "genes": [
            "DNMT3A",
            "FLT3"
          ],
          "targets": [
            "DNMT3A"
          ],
          "approvalStatus": "approved",
          "isApproved": true,
          "gene": "DNMT3A",
          "source": "DGIdb",
          "targetId": null,
          "targetsMultipleGenes": true,
          "pubchem": {
            "cid": 451668,
            "molecularWeight": "228.21",
            "xlogp": -1.2,
            "inchikey": "XAUDJQYHKZQPEU-KVQBGUIXSA-N",
            "iupacName": "4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one",
            "source": "PubChem"
          }
        },
        {
          "name": "IDARUBICIN",
          "chemblId": "rxcui:5650",
          "maxPhase": 4,
          "phaseLabel": "FDA Approved",
          "pChEMBL": null,
          "potency": "Interaction: Unknown",
          "sources": [
            "DGIdb"
          ],
          "validated": "single-source",
          "sourceCount": 1,
          "pmids": [],
          "genes": [
            "DNMT3A",
            "FLT3"
          ],
          "targets": [
            "DNMT3A"
          ],
          "approvalStatus": "approved",
          "isApproved": true,
          "gene": "DNMT3A",
          "source": "DGIdb",
          "targetId": null,
          "targetsMultipleGenes": true,
          "pubchem": {
            "cid": 42890,
            "molecularWeight": "497.5",
            "xlogp": 1.9,
            "inchikey": "XDXDZDZNSLXDNA-TZNDIEGXSA-N",
            "iupacName": "(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione",
            "source": "PubChem"
          }
        },
        {
          "name": "TALAZOPARIB",
          "chemblId": "rxcui:2099704",
          "maxPhase": 4,
          "phaseLabel": "FDA Approved",
          "pChEMBL": null,
          "potency": "Interaction: Unknown",
          "sources": [
            "DGIdb"
          ],
          "validated": "single-source",
          "sourceCount": 1,
          "pmids": [
            34215619
          ],
          "genes": [
            "DNMT3A",
            "FLT3"
          ],
          "targets": [
            "DNMT3A"
          ],
          "approvalStatus": "approved",
          "isApproved": true,
          "gene": "DNMT3A",
          "source": "DGIdb",
          "targetId": null,
          "targetsMultipleGenes": true,
          "pubchem": {
            "cid": 135565082,
            "molecularWeight": "380.4",
            "xlogp": 2.3,
            "inchikey": "HWGQMRYQVZSGDQ-HZPDHXFCSA-N",
            "iupacName": "(11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8-tetraen-4-one",
            "source": "PubChem"
          }
        },
        {
          "name": "OLAPARIB",
          "chemblId": "rxcui:1597582",
          "maxPhase": 4,
          "phaseLabel": "FDA Approved",
          "pChEMBL": null,
          "potency": "Interaction: Unknown",
          "sources": [
            "DGIdb"
          ],
          "validated": "single-source",
          "sourceCount": 1,
          "pmids": [
            34215619
          ],
          "genes": [
            "DNMT3A",
            "FLT3"
          ],
          "targets": [
            "DNMT3A"
          ],
          "approvalStatus": "approved",
          "isApproved": true,
          "gene": "DNMT3A",
          "source": "DGIdb",
          "targetId": null,
          "targetsMultipleGenes": true,
          "pubchem": {
            "cid": 23725625,
            "molecularWeight": "434.5",
            "xlogp": 1.9,
            "inchikey": "FDLYAMZZIXQODN-UHFFFAOYSA-N",
            "iupacName": "4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one",
            "source": "PubChem"
          }
        },
        {
          "name": "DOXORUBICIN HYDROCHLORIDE",
          "chemblId": "rxcui:142433",
          "maxPhase": 4,
          "phaseLabel": "FDA Approved",
          "pChEMBL": null,
          "potency": "Interaction: Unknown",
          "sources": [
            "DGIdb"
          ],
          "validated": "single-source",
          "sourceCount": 1,
          "pmids": [
            34215619
          ],
          "genes": [
            "DNMT3A",
            "FLT3"
          ],
          "targets": [
            "DNMT3A"
          ],
          "approvalStatus": "approved",
          "isApproved": true,
          "gene": "DNMT3A",
          "source": "DGIdb",
          "targetId": null,
          "targetsMultipleGenes": true,
          "pubchem": {
            "cid": 443939,
            "molecularWeight": "580.0",
            "inchikey": "MWWSFMDVAYGXBV-RUELKSSGSA-N",
            "iupacName": "(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride",
            "source": "PubChem"
          }
        },
        {
          "name": "TRAMETINIB DIMETHYL SULFOXIDE",
          "chemblId": "rxcui:1425098",
          "maxPhase": 4,
          "phaseLabel": "FDA Approved",
          "pChEMBL": null,
          "potency": "Interaction: Unknown",
          "sources": [
            "DGIdb"
          ],
          "validated": "single-source",
          "sourceCount": 1,
          "pmids": [
            31164355
          ],
          "genes": [
            "DNMT3A",
            "FLT3"
          ],
          "targets": [
            "DNMT3A"
          ],
          "approvalStatus": "approved",
          "isApproved": true,
          "gene": "DNMT3A",
          "source": "DGIdb",
          "targetId": null,
          "targetsMultipleGenes": true,
          "pubchem": {
            "cid": 50992434,
            "molecularWeight": "693.5",
            "inchikey": "OQUFJVRYDFIQBW-UHFFFAOYSA-N",
            "iupacName": "N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide;methylsulfinylmethane",
            "source": "PubChem"
          }
        },
        {
          "name": "VENETOCLAX",
          "chemblId": "rxcui:1747556",
          "maxPhase": 4,
          "phaseLabel": "FDA Approved",
          "pChEMBL": null,
          "potency": "Interaction: Unknown",
          "sources": [
            "DGIdb"
          ],
          "validated": "single-source",
          "sourceCount": 4,
          "pmids": [
            35017466,
            38968731,
            34732043,
            39180903,
            38277619,
            35849791,
            33563661,
            38007585,
            31751472,
            37992684
          ],
          "genes": [
            "FLT3",
            "NPM1"
          ],
          "targets": [
            "FLT3"
          ],
          "approvalStatus": "approved",
          "isApproved": true,
          "gene": "FLT3",
          "source": "DGIdb",
          "targetId": null,
          "targetsMultipleGenes": true,
          "pubchem": {
            "cid": 49846579,
            "molecularWeight": "868.4",
            "xlogp": 8.2,
            "inchikey": "LQBVNQSMGBZMKD-UHFFFAOYSA-N",
            "iupacName": "4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide",
            "source": "PubChem"
          }
        }
      ],
      "approvedDrugs": [],
      "multiTargetCompounds": [
        {
          "name": "DAUNORUBICIN LIPOSOMAL",
          "chemblId": "rxcui:214468",
          "targets": [
            "DNMT3A",
            "FLT3",
            "NPM1"
          ],
          "targetCount": 3,
          "phase": "FDA Approved",
          "potency": "Interaction: Unknown",
          "pChEMBL": null,
          "role": "pan-inhibitor"
        },
        {
          "name": "AZACITIDINE",
          "chemblId": "rxcui:1251",
          "targets": [
            "DNMT3A",
            "FLT3"
          ],
          "targetCount": 2,
          "phase": "FDA Approved",
          "potency": "Interaction: inhibitor",
          "pChEMBL": null,
          "role": "pan-inhibitor"
        },
        {
          "name": "QUIZARTINIB",
          "chemblId": "rxcui:2643048",
          "targets": [
            "DNMT3A",
            "FLT3"
          ],
          "targetCount": 2,
          "phase": "FDA Approved",
          "potency": "Interaction: Unknown",
          "pChEMBL": null,
          "role": "pan-inhibitor"
        },
        {
          "name": "DECITABINE",
          "chemblId": "rxcui:15657",
          "targets": [
            "DNMT3A",
            "FLT3"
          ],
          "targetCount": 2,
          "phase": "FDA Approved",
          "potency": "Interaction: inhibitor",
          "pChEMBL": null,
          "role": "pan-inhibitor"
        },
        {
          "name": "IDARUBICIN",
          "chemblId": "rxcui:5650",
          "targets": [
            "DNMT3A",
            "FLT3"
          ],
          "targetCount": 2,
          "phase": "FDA Approved",
          "potency": "Interaction: Unknown",
          "pChEMBL": null,
          "role": "pan-inhibitor"
        }
      ]
    },
    "drugRepurposing": {
      "candidates": [
        {
          "drug": "DAUNORUBICIN LIPOSOMAL",
          "drugId": "rxcui:214468",
          "repurposingScore": 45,
          "confidence": "medium",
          "breakdown": {
            "targetMatch": 33.33333333333333,
            "pathwayOverlap": 0,
            "clinicalEvidence": 100,
            "safetyProfile": 100,
            "mechanismRelevance": 0
          },
          "matchedTargets": [
            "DNMT3A"
          ],
          "currentIndication": "Unknown",
          "proposedIndication": "acute myeloid leukemia",
          "mechanism": "Not specified",
          "phase": "FDA Approved",
          "estimatedSavings": {
            "cost": "$1035M - $1535M",
            "time": "8 - 10 years faster",
            "confidence": "medium"
          },
          "reasoning": [
            "⚠️ Partial target match (33%)",
            "✅ FDA approved with proven safety profile"
          ]
        },
        {
          "drug": "AZACITIDINE",
          "drugId": "rxcui:1251",
          "repurposingScore": 45,
          "confidence": "medium",
          "breakdown": {
            "targetMatch": 33.33333333333333,
            "pathwayOverlap": 0,
            "clinicalEvidence": 100,
            "safetyProfile": 100,
            "mechanismRelevance": 0
          },
          "matchedTargets": [
            "DNMT3A"
          ],
          "currentIndication": "Unknown",
          "proposedIndication": "acute myeloid leukemia",
          "mechanism": "Not specified",
          "phase": "FDA Approved",
          "estimatedSavings": {
            "cost": "$1035M - $1535M",
            "time": "8 - 10 years faster",
            "confidence": "medium"
          },
          "reasoning": [
            "⚠️ Partial target match (33%)",
            "✅ FDA approved with proven safety profile"
          ]
        },
        {
          "drug": "QUIZARTINIB",
          "drugId": "rxcui:2643048",
          "repurposingScore": 45,
          "confidence": "medium",
          "breakdown": {
            "targetMatch": 33.33333333333333,
            "pathwayOverlap": 0,
            "clinicalEvidence": 100,
            "safetyProfile": 100,
            "mechanismRelevance": 0
          },
          "matchedTargets": [
            "DNMT3A"
          ],
          "currentIndication": "Unknown",
          "proposedIndication": "acute myeloid leukemia",
          "mechanism": "Not specified",
          "phase": "FDA Approved",
          "estimatedSavings": {
            "cost": "$1035M - $1535M",
            "time": "8 - 10 years faster",
            "confidence": "medium"
          },
          "reasoning": [
            "⚠️ Partial target match (33%)",
            "✅ FDA approved with proven safety profile"
          ]
        },
        {
          "drug": "DECITABINE",
          "drugId": "rxcui:15657",
          "repurposingScore": 45,
          "confidence": "medium",
          "breakdown": {
            "targetMatch": 33.33333333333333,
            "pathwayOverlap": 0,
            "clinicalEvidence": 100,
            "safetyProfile": 100,
            "mechanismRelevance": 0
          },
          "matchedTargets": [
            "DNMT3A"
          ],
          "currentIndication": "Unknown",
          "proposedIndication": "acute myeloid leukemia",
          "mechanism": "Not specified",
          "phase": "FDA Approved",
          "estimatedSavings": {
            "cost": "$1035M - $1535M",
            "time": "8 - 10 years faster",
            "confidence": "medium"
          },
          "reasoning": [
            "⚠️ Partial target match (33%)",
            "✅ FDA approved with proven safety profile"
          ]
        },
        {
          "drug": "IDARUBICIN",
          "drugId": "rxcui:5650",
          "repurposingScore": 45,
          "confidence": "medium",
          "breakdown": {
            "targetMatch": 33.33333333333333,
            "pathwayOverlap": 0,
            "clinicalEvidence": 100,
            "safetyProfile": 100,
            "mechanismRelevance": 0
          },
          "matchedTargets": [
            "DNMT3A"
          ],
          "currentIndication": "Unknown",
          "proposedIndication": "acute myeloid leukemia",
          "mechanism": "Not specified",
          "phase": "FDA Approved",
          "estimatedSavings": {
            "cost": "$1035M - $1535M",
            "time": "8 - 10 years faster",
            "confidence": "medium"
          },
          "reasoning": [
            "⚠️ Partial target match (33%)",
            "✅ FDA approved with proven safety profile"
          ]
        },
        {
          "drug": "TALAZOPARIB",
          "drugId": "rxcui:2099704",
          "repurposingScore": 45,
          "confidence": "medium",
          "breakdown": {
            "targetMatch": 33.33333333333333,
            "pathwayOverlap": 0,
            "clinicalEvidence": 100,
            "safetyProfile": 100,
            "mechanismRelevance": 0
          },
          "matchedTargets": [
            "DNMT3A"
          ],
          "currentIndication": "Unknown",
          "proposedIndication": "acute myeloid leukemia",
          "mechanism": "Not specified",
          "phase": "FDA Approved",
          "estimatedSavings": {
            "cost": "$1035M - $1535M",
            "time": "8 - 10 years faster",
            "confidence": "medium"
          },
          "reasoning": [
            "⚠️ Partial target match (33%)",
            "✅ FDA approved with proven safety profile"
          ]
        },
        {
          "drug": "OLAPARIB",
          "drugId": "rxcui:1597582",
          "repurposingScore": 45,
          "confidence": "medium",
          "breakdown": {
            "targetMatch": 33.33333333333333,
            "pathwayOverlap": 0,
            "clinicalEvidence": 100,
            "safetyProfile": 100,
            "mechanismRelevance": 0
          },
          "matchedTargets": [
            "DNMT3A"
          ],
          "currentIndication": "Unknown",
          "proposedIndication": "acute myeloid leukemia",
          "mechanism": "Not specified",
          "phase": "FDA Approved",
          "estimatedSavings": {
            "cost": "$1035M - $1535M",
            "time": "8 - 10 years faster",
            "confidence": "medium"
          },
          "reasoning": [
            "⚠️ Partial target match (33%)",
            "✅ FDA approved with proven safety profile"
          ]
        },
        {
          "drug": "DOXORUBICIN HYDROCHLORIDE",
          "drugId": "rxcui:142433",
          "repurposingScore": 45,
          "confidence": "medium",
          "breakdown": {
            "targetMatch": 33.33333333333333,
            "pathwayOverlap": 0,
            "clinicalEvidence": 100,
            "safetyProfile": 100,
            "mechanismRelevance": 0
          },
          "matchedTargets": [
            "DNMT3A"
          ],
          "currentIndication": "Unknown",
          "proposedIndication": "acute myeloid leukemia",
          "mechanism": "Not specified",
          "phase": "FDA Approved",
          "estimatedSavings": {
            "cost": "$1035M - $1535M",
            "time": "8 - 10 years faster",
            "confidence": "medium"
          },
          "reasoning": [
            "⚠️ Partial target match (33%)",
            "✅ FDA approved with proven safety profile"
          ]
        },
        {
          "drug": "TRAMETINIB DIMETHYL SULFOXIDE",
          "drugId": "rxcui:1425098",
          "repurposingScore": 45,
          "confidence": "medium",
          "breakdown": {
            "targetMatch": 33.33333333333333,
            "pathwayOverlap": 0,
            "clinicalEvidence": 100,
            "safetyProfile": 100,
            "mechanismRelevance": 0
          },
          "matchedTargets": [
            "DNMT3A"
          ],
          "currentIndication": "Unknown",
          "proposedIndication": "acute myeloid leukemia",
          "mechanism": "Not specified",
          "phase": "FDA Approved",
          "estimatedSavings": {
            "cost": "$1035M - $1535M",
            "time": "8 - 10 years faster",
            "confidence": "medium"
          },
          "reasoning": [
            "⚠️ Partial target match (33%)",
            "✅ FDA approved with proven safety profile"
          ]
        },
        {
          "drug": "VENETOCLAX",
          "drugId": "rxcui:1747556",
          "repurposingScore": 45,
          "confidence": "medium",
          "breakdown": {
            "targetMatch": 33.33333333333333,
            "pathwayOverlap": 0,
            "clinicalEvidence": 100,
            "safetyProfile": 100,
            "mechanismRelevance": 0
          },
          "matchedTargets": [
            "FLT3"
          ],
          "currentIndication": "Unknown",
          "proposedIndication": "acute myeloid leukemia",
          "mechanism": "Not specified",
          "phase": "FDA Approved",
          "estimatedSavings": {
            "cost": "$1035M - $1535M",
            "time": "8 - 10 years faster",
            "confidence": "medium"
          },
          "reasoning": [
            "⚠️ Partial target match (33%)",
            "✅ FDA approved with proven safety profile"
          ]
        }
      ],
      "stats": {
        "totalDrugsAnalyzed": 203,
        "candidatesFound": 10,
        "avgScore": 45,
        "analysisTime": "1ms",
        "minScore": 30,
        "onlyApproved": false
      },
      "summary": {
        "headline": "10 drug repurposing candidates identified for acute myeloid leukemia",
        "summary": "Top candidate: DAUNORUBICIN LIPOSOMAL (45% match). 10 FDA-approved drugs found.",
        "recommendation": "Prioritize DAUNORUBICIN LIPOSOMAL for experimental validation. Estimated savings: $1035M - $1535M vs. new drug development.",
        "commercialValue": "Enterprise feature worth $10K-50K/year. Total potential savings across 10 candidates: $15000M - $25000M."
      },
      "enterpriseValue": "$10K-50K/year",
      "timestamp": "2026-01-15T21:16:39.285Z"
    },
    "novelHypotheses": {
      "hypotheses": [
        {
          "type": "drug_repurposing",
          "statement": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
          "drug": "DAUNORUBICIN LIPOSOMAL",
          "drugId": "rxcui:214468",
          "disease": "acute myeloid leukemia",
          "currentIndication": "Unknown",
          "mechanism": "Targets DNMT3A, FLT3, NPM1 which are implicated in disease",
          "score": 1,
          "evidence": [
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            }
          ],
          "supportingEvidence": 0,
          "contradictingEvidence": 0,
          "evidenceBalance": 0,
          "novelty": 0.85,
          "testable": true,
          "clinicalPhase": 4,
          "approved": true,
          "confidence": 0.8999999999999999,
          "impact": 0.95,
          "plausibility": 0.8599999999999999,
          "evidenceStrength": 1,
          "contradictionPenalty": 0,
          "supportingEvidenceItems": [],
          "contradictingEvidenceItems": [],
          "mixedEvidenceItems": [],
          "neutralEvidenceItems": [
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "NPM1",
              "description": "Drug targets gene associated with disease",
              "weight": 0.656
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            }
          ],
          "supportingPmids": [],
          "contradictingPmids": [],
          "noveltyRationale": "Highly novel; limited direct literature links, multi-source evidence support.",
          "noveltySignals": {
            "directEvidenceScore": 0,
            "evidenceStrength": 1,
            "supportingEvidence": 0,
            "contradictingEvidence": 0
          },
          "totalScore": 0.8939999999999999,
          "scorecard": {
            "confidence": 0.8999999999999999,
            "novelty": 0.85,
            "impact": 0.95,
            "plausibility": 0.8599999999999999,
            "evidenceStrength": 1,
            "contradictionPenalty": 0,
            "supporting": 0,
            "contradicting": 0,
            "mixed": 0,
            "neutral": 56,
            "supportWeight": 0,
            "contradictWeight": 0
          },
          "rank": 1,
          "experimentalDesign": {
            "hypothesis": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
            "experimentType": "In Vitro Efficacy + Mechanism Validation",
            "protocol": [
              "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
              "2. Treat with DAUNORUBICIN LIPOSOMAL across a dose range (8-12 concentrations)",
              "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
              "4. Validate on-target engagement with western blot or target-specific assays"
            ],
            "controls": [
              "Vehicle control (DMSO)",
              "Known standard-of-care drug (positive control)",
              "Off-target negative control compound"
            ],
            "readouts": [
              "Dose-response curve and IC50",
              "Biomarker modulation (pathway activation/inhibition)",
              "Cell cycle profiling (flow cytometry)",
              "Transcriptomic response signature"
            ],
            "timeline": "3-6 weeks",
            "estimatedCost": "$10,000-20,000",
            "successCriteria": "Significant efficacy vs control with IC50 < 1 μM and biomarker modulation",
            "predictedOutcome": "90% probability of efficacy",
            "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
          },
          "id": "1b58d2f52108e96e",
          "shareUrl": "http://localhost:8787/hypothesis/1b58d2f52108e96e",
          "reportValidationUrl": "http://localhost:8787/api/validate/1b58d2f52108e96e"
        },
        {
          "type": "drug_repurposing",
          "statement": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
          "drug": "AZACITIDINE",
          "drugId": "rxcui:1251",
          "disease": "acute myeloid leukemia",
          "currentIndication": "Unknown",
          "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
          "score": 0.8357142857142856,
          "evidence": [
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            }
          ],
          "supportingEvidence": 0,
          "contradictingEvidence": 0,
          "evidenceBalance": 0,
          "novelty": 0.85,
          "testable": true,
          "clinicalPhase": 4,
          "approved": true,
          "confidence": 0.8671428571428571,
          "impact": 0.95,
          "plausibility": 0.814,
          "evidenceStrength": 1,
          "contradictionPenalty": 0,
          "supportingEvidenceItems": [],
          "contradictingEvidenceItems": [],
          "mixedEvidenceItems": [],
          "neutralEvidenceItems": [
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            }
          ],
          "supportingPmids": [],
          "contradictingPmids": [],
          "noveltyRationale": "Highly novel; limited direct literature links, multi-source evidence support.",
          "noveltySignals": {
            "directEvidenceScore": 0,
            "evidenceStrength": 1,
            "supportingEvidence": 0,
            "contradictingEvidence": 0
          },
          "totalScore": 0.8756,
          "scorecard": {
            "confidence": 0.8671428571428571,
            "novelty": 0.85,
            "impact": 0.95,
            "plausibility": 0.814,
            "evidenceStrength": 1,
            "contradictionPenalty": 0,
            "supporting": 0,
            "contradicting": 0,
            "mixed": 0,
            "neutral": 30,
            "supportWeight": 0,
            "contradictWeight": 0
          },
          "rank": 2,
          "experimentalDesign": {
            "hypothesis": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
            "experimentType": "In Vitro Efficacy + Mechanism Validation",
            "protocol": [
              "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
              "2. Treat with AZACITIDINE across a dose range (8-12 concentrations)",
              "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
              "4. Validate on-target engagement with western blot or target-specific assays"
            ],
            "controls": [
              "Vehicle control (DMSO)",
              "Known standard-of-care drug (positive control)",
              "Off-target negative control compound"
            ],
            "readouts": [
              "Dose-response curve and IC50",
              "Biomarker modulation (pathway activation/inhibition)",
              "Cell cycle profiling (flow cytometry)",
              "Transcriptomic response signature"
            ],
            "timeline": "3-6 weeks",
            "estimatedCost": "$10,000-20,000",
            "successCriteria": "Significant efficacy vs control with IC50 < 1 μM and biomarker modulation",
            "predictedOutcome": "87% probability of efficacy",
            "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
          },
          "id": "7022f99bce9e2693",
          "shareUrl": "http://localhost:8787/hypothesis/7022f99bce9e2693",
          "reportValidationUrl": "http://localhost:8787/api/validate/7022f99bce9e2693"
        },
        {
          "type": "drug_repurposing",
          "statement": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
          "drug": "QUIZARTINIB",
          "drugId": "rxcui:2643048",
          "disease": "acute myeloid leukemia",
          "currentIndication": "Unknown",
          "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
          "score": 0.8357142857142856,
          "evidence": [
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            }
          ],
          "supportingEvidence": 0,
          "contradictingEvidence": 0,
          "evidenceBalance": 0,
          "novelty": 0.85,
          "testable": true,
          "clinicalPhase": 4,
          "approved": true,
          "confidence": 0.8671428571428571,
          "impact": 0.95,
          "plausibility": 0.814,
          "evidenceStrength": 1,
          "contradictionPenalty": 0,
          "supportingEvidenceItems": [],
          "contradictingEvidenceItems": [],
          "mixedEvidenceItems": [],
          "neutralEvidenceItems": [
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            }
          ],
          "supportingPmids": [],
          "contradictingPmids": [],
          "noveltyRationale": "Highly novel; limited direct literature links, multi-source evidence support.",
          "noveltySignals": {
            "directEvidenceScore": 0,
            "evidenceStrength": 1,
            "supportingEvidence": 0,
            "contradictingEvidence": 0
          },
          "totalScore": 0.8756,
          "scorecard": {
            "confidence": 0.8671428571428571,
            "novelty": 0.85,
            "impact": 0.95,
            "plausibility": 0.814,
            "evidenceStrength": 1,
            "contradictionPenalty": 0,
            "supporting": 0,
            "contradicting": 0,
            "mixed": 0,
            "neutral": 30,
            "supportWeight": 0,
            "contradictWeight": 0
          },
          "rank": 3,
          "experimentalDesign": {
            "hypothesis": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
            "experimentType": "In Vitro Efficacy + Mechanism Validation",
            "protocol": [
              "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
              "2. Treat with QUIZARTINIB across a dose range (8-12 concentrations)",
              "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
              "4. Validate on-target engagement with western blot or target-specific assays"
            ],
            "controls": [
              "Vehicle control (DMSO)",
              "Known standard-of-care drug (positive control)",
              "Off-target negative control compound"
            ],
            "readouts": [
              "Dose-response curve and IC50",
              "Biomarker modulation (pathway activation/inhibition)",
              "Cell cycle profiling (flow cytometry)",
              "Transcriptomic response signature"
            ],
            "timeline": "3-6 weeks",
            "estimatedCost": "$10,000-20,000",
            "successCriteria": "Significant efficacy vs control with IC50 < 1 μM and biomarker modulation",
            "predictedOutcome": "87% probability of efficacy",
            "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
          },
          "id": "4dfff9cdffee13df",
          "shareUrl": "http://localhost:8787/hypothesis/4dfff9cdffee13df",
          "reportValidationUrl": "http://localhost:8787/api/validate/4dfff9cdffee13df"
        },
        {
          "type": "drug_repurposing",
          "statement": "DECITABINE may be repurposed to treat acute myeloid leukemia",
          "drug": "DECITABINE",
          "drugId": "rxcui:15657",
          "disease": "acute myeloid leukemia",
          "currentIndication": "Unknown",
          "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
          "score": 0.8357142857142856,
          "evidence": [
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            }
          ],
          "supportingEvidence": 0,
          "contradictingEvidence": 0,
          "evidenceBalance": 0,
          "novelty": 0.85,
          "testable": true,
          "clinicalPhase": 4,
          "approved": true,
          "confidence": 0.8671428571428571,
          "impact": 0.95,
          "plausibility": 0.814,
          "evidenceStrength": 1,
          "contradictionPenalty": 0,
          "supportingEvidenceItems": [],
          "contradictingEvidenceItems": [],
          "mixedEvidenceItems": [],
          "neutralEvidenceItems": [
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            }
          ],
          "supportingPmids": [],
          "contradictingPmids": [],
          "noveltyRationale": "Highly novel; limited direct literature links, multi-source evidence support.",
          "noveltySignals": {
            "directEvidenceScore": 0,
            "evidenceStrength": 1,
            "supportingEvidence": 0,
            "contradictingEvidence": 0
          },
          "totalScore": 0.8756,
          "scorecard": {
            "confidence": 0.8671428571428571,
            "novelty": 0.85,
            "impact": 0.95,
            "plausibility": 0.814,
            "evidenceStrength": 1,
            "contradictionPenalty": 0,
            "supporting": 0,
            "contradicting": 0,
            "mixed": 0,
            "neutral": 30,
            "supportWeight": 0,
            "contradictWeight": 0
          },
          "rank": 4,
          "experimentalDesign": {
            "hypothesis": "DECITABINE may be repurposed to treat acute myeloid leukemia",
            "experimentType": "In Vitro Efficacy + Mechanism Validation",
            "protocol": [
              "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
              "2. Treat with DECITABINE across a dose range (8-12 concentrations)",
              "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
              "4. Validate on-target engagement with western blot or target-specific assays"
            ],
            "controls": [
              "Vehicle control (DMSO)",
              "Known standard-of-care drug (positive control)",
              "Off-target negative control compound"
            ],
            "readouts": [
              "Dose-response curve and IC50",
              "Biomarker modulation (pathway activation/inhibition)",
              "Cell cycle profiling (flow cytometry)",
              "Transcriptomic response signature"
            ],
            "timeline": "3-6 weeks",
            "estimatedCost": "$10,000-20,000",
            "successCriteria": "Significant efficacy vs control with IC50 < 1 μM and biomarker modulation",
            "predictedOutcome": "87% probability of efficacy",
            "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
          },
          "id": "8ce069c910d80c86",
          "shareUrl": "http://localhost:8787/hypothesis/8ce069c910d80c86",
          "reportValidationUrl": "http://localhost:8787/api/validate/8ce069c910d80c86"
        },
        {
          "type": "drug_repurposing",
          "statement": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
          "drug": "IDARUBICIN",
          "drugId": "rxcui:5650",
          "disease": "acute myeloid leukemia",
          "currentIndication": "Unknown",
          "mechanism": "Targets DNMT3A, FLT3 which are implicated in disease",
          "score": 0.8357142857142856,
          "evidence": [
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            }
          ],
          "supportingEvidence": 0,
          "contradictingEvidence": 0,
          "evidenceBalance": 0,
          "novelty": 0.85,
          "testable": true,
          "clinicalPhase": 4,
          "approved": true,
          "confidence": 0.8671428571428571,
          "impact": 0.95,
          "plausibility": 0.814,
          "evidenceStrength": 1,
          "contradictionPenalty": 0,
          "supportingEvidenceItems": [],
          "contradictingEvidenceItems": [],
          "mixedEvidenceItems": [],
          "neutralEvidenceItems": [
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "DNMT3A",
              "description": "Drug targets gene associated with disease",
              "weight": 0.817
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            },
            {
              "type": "target_overlap",
              "gene": "FLT3",
              "description": "Drug targets gene associated with disease",
              "weight": 0.809
            }
          ],
          "supportingPmids": [],
          "contradictingPmids": [],
          "noveltyRationale": "Highly novel; limited direct literature links, multi-source evidence support.",
          "noveltySignals": {
            "directEvidenceScore": 0,
            "evidenceStrength": 1,
            "supportingEvidence": 0,
            "contradictingEvidence": 0
          },
          "totalScore": 0.8756,
          "scorecard": {
            "confidence": 0.8671428571428571,
            "novelty": 0.85,
            "impact": 0.95,
            "plausibility": 0.814,
            "evidenceStrength": 1,
            "contradictionPenalty": 0,
            "supporting": 0,
            "contradicting": 0,
            "mixed": 0,
            "neutral": 30,
            "supportWeight": 0,
            "contradictWeight": 0
          },
          "rank": 5,
          "experimentalDesign": {
            "hypothesis": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
            "experimentType": "In Vitro Efficacy + Mechanism Validation",
            "protocol": [
              "1. Select disease-relevant cell lines or organoids for acute myeloid leukemia",
              "2. Treat with IDARUBICIN across a dose range (8-12 concentrations)",
              "3. Measure viability, apoptosis, and pathway biomarkers at 24h/72h",
              "4. Validate on-target engagement with western blot or target-specific assays"
            ],
            "controls": [
              "Vehicle control (DMSO)",
              "Known standard-of-care drug (positive control)",
              "Off-target negative control compound"
            ],
            "readouts": [
              "Dose-response curve and IC50",
              "Biomarker modulation (pathway activation/inhibition)",
              "Cell cycle profiling (flow cytometry)",
              "Transcriptomic response signature"
            ],
            "timeline": "3-6 weeks",
            "estimatedCost": "$10,000-20,000",
            "successCriteria": "Significant efficacy vs control with IC50 < 1 μM and biomarker modulation",
            "predictedOutcome": "87% probability of efficacy",
            "expectedOutcome": "Exploratory outcome; limited direct evidence in current graph."
          },
          "id": "8a7ff51eaf259620",
          "shareUrl": "http://localhost:8787/hypothesis/8a7ff51eaf259620",
          "reportValidationUrl": "http://localhost:8787/api/validate/8a7ff51eaf259620"
        }
      ],
      "stats": {
        "candidatesGenerated": 5,
        "hypothesesReturned": 5,
        "avgConfidence": 0.8737142857142857,
        "avgNovelty": 0.85,
        "generationTime": "32ms",
        "graphSize": {
          "nodes": 248,
          "edges": 298
        }
      },
      "metadata": {
        "timestamp": "2026-01-15T21:16:47.523Z",
        "diseaseContext": "acute myeloid leukemia",
        "geneCount": 3,
        "minConfidence": 0.65,
        "noveltyThreshold": 0.7
      },
      "accuracyStats": {
        "overallAccuracy": 0,
        "totalHypotheses": 317,
        "totalValidations": 0,
        "confirmed": 0,
        "rejected": 0,
        "partial": 0,
        "pending": 0,
        "accuracyByType": {},
        "trustScore": 0,
        "message": "Building trust - Testing predictions in the lab"
      },
      "enterpriseValue": "$100K-500K/year",
      "patentPotential": "HIGH - Novel predictions can be patented",
      "revolutionaryNote": "These predictions go BEYOND existing literature - they are NEW knowledge generated by AI",
      "learningNote": "AI improves with every validation. Current accuracy: 0.0% based on 0 validations"
    },
    "citations": [
      {
        "pmid": "39115831",
        "citation": "Venugopal S, Sekeres MA. Contemporary Management of Acute Myeloid Leukemia: A Review.. JAMA oncology. 2024.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/39115831/"
      },
      {
        "pmid": "40615295",
        "citation": "Boussi L, Cai SF, Stein EM. Advances in menin inhibition in acute myeloid leukemia.. Trends in cancer. 2025.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/40615295/"
      },
      {
        "pmid": "39195279",
        "citation": "Nong T, Mehra S, Taylor J. Common Driver Mutations in AML: Biological Impact, Clinical Considerations, and Treatment Strategies.. Cells. 2024.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/39195279/"
      },
      {
        "pmid": "39558390",
        "citation": "Nadiminti KVG, Sahasrabudhe KD, Liu H. Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead.. Journal of hematology & oncology. 2024.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/39558390/"
      },
      {
        "pmid": "38969930",
        "citation": "Jafari PA, Bagheri R, Lavasani S. DNMT3A-R882: a mutation with many paradoxes.. Annals of hematology. 2024.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/38969930/"
      },
      {
        "pmid": "38651453",
        "citation": "Candoni A, Coppola G. A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia.. Hematology reports. 2024.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/38651453/"
      },
      {
        "pmid": "40818987",
        "citation": "Gangat N, Dinardo CD. Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms.. Blood cancer journal. 2025.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/40818987/"
      },
      {
        "pmid": "39901865",
        "citation": "Chen EC, Shimony S, Luskin MR. Biology and Management of Acute Myeloid Leukemia With Mutated NPM1.. American journal of hematology. 2025.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/39901865/"
      },
      {
        "pmid": "41280924",
        "citation": "Zanetti LC, Tomaz V, de Souza IF. Precision medicine with car cells in acute myeloid leukemia: where are we?. Frontiers in immunology. 2025.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41280924/"
      },
      {
        "pmid": "40105906",
        "citation": "Senapati J, Kadia TM, Daver NG. Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges.. Cancer. 2025.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/40105906/"
      },
      {
        "pmid": "39719041",
        "citation": "Huls G, Woolthuis CM, Schuringa JJ. Menin inhibitors in the treatment of acute myeloid leukemia.. Blood. 2025.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/39719041/"
      },
      {
        "pmid": "38691678",
        "citation": "Othman J, Potter N, Ivey A. Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.. Blood. 2024.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/38691678/"
      },
      {
        "pmid": "39085680",
        "citation": "Urrutia S, Takahashi K. Precision medicine in AML: overcoming resistance.. International journal of hematology. 2024.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/39085680/"
      },
      {
        "pmid": "39690184",
        "citation": "Falini B, Sorcini D, Perriello VM. Functions of the native NPM1 protein and its leukemic mutant.. Leukemia. 2025.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/39690184/"
      },
      {
        "pmid": "38905635",
        "citation": "Kwon MC, Thuring JW, Querolle O. Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias.. Blood. 2024.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/38905635/"
      },
      {
        "pmid": "40910580",
        "citation": "Garcia-Rodriguez MJ, Flores Y, Salinas J. Acute myeloid leukemia: a comprehensive update.. Current opinion in hematology. 2025.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/40910580/"
      },
      {
        "pmid": "40409258",
        "citation": "Sirenko M, Lee S, Sun Z. Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia.. Cell stem cell. 2025.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/40409258/"
      },
      {
        "pmid": "39180903",
        "citation": "Fu Q, Wang Y, Liu H. Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3 acute myeloid leukemia.. Leukemia research. 2024.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/39180903/"
      },
      {
        "pmid": "38364112",
        "citation": "Othman J, Potter N, Ivey A. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.. Blood. 2024.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/38364112/"
      },
      {
        "pmid": "40590852",
        "citation": "Levis MJ, Hamadani M, Logan BR. Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.. Blood advances. 2025.",
        "url": "https://pubmed.ncbi.nlm.nih.gov/40590852/"
      }
    ],
    "citationCounts": {
      "38364112": 49,
      "38437498": 21,
      "38651453": 45,
      "38691678": 50,
      "38905635": 39,
      "38969930": 1,
      "39085680": 5,
      "39115831": 44,
      "39180903": 7,
      "39195279": 15,
      "39558390": 17,
      "39690184": 14,
      "39704147": 6,
      "39719041": 12,
      "39841016": 5,
      "39901865": 6,
      "39987368": 5,
      "40105906": 9,
      "40269321": 10,
      "40332046": 17,
      "40396900": 4,
      "40409258": 5,
      "40590852": 2,
      "40615295": 3,
      "40662375": 1,
      "40818987": 9,
      "40829168": 0,
      "40910580": 1,
      "41192422": 1,
      "41280924": 1
    },
    "openAccessMap": {
      "38437498": "https://doi.org/10.1101/2023.09.28.560054",
      "38651453": "https://www.mdpi.com/2038-8330/16/2/24/pdf?version=1713434481",
      "39195279": "https://doi.org/10.3390/cells13161392",
      "40269321": "https://doi.org/10.1038/s41587-025-02648-2"
    },
    "leadingResearchers": [
      {
        "name": "Nigel H. Russell",
        "paperCount": 2,
        "totalCitations": 99,
        "avgCitations": 50,
        "topPaper": {
          "pmid": "38691678",
          "title": "Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.",
          "year": "2024",
          "citationCount": 50
        },
        "role": "Senior Researcher"
      },
      {
        "name": "J. Othman",
        "paperCount": 2,
        "totalCitations": 99,
        "avgCitations": 50,
        "topPaper": {
          "pmid": "38691678",
          "title": "Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.",
          "year": "2024",
          "citationCount": 50
        },
        "role": "Active Contributor"
      },
      {
        "name": "N. Potter",
        "paperCount": 2,
        "totalCitations": 99,
        "avgCitations": 50,
        "topPaper": {
          "pmid": "38691678",
          "title": "Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.",
          "year": "2024",
          "citationCount": 50
        },
        "role": "Active Contributor"
      },
      {
        "name": "Adam Ivey",
        "paperCount": 2,
        "totalCitations": 99,
        "avgCitations": 50,
        "topPaper": {
          "pmid": "38691678",
          "title": "Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.",
          "year": "2024",
          "citationCount": 50
        },
        "role": "Active Contributor"
      },
      {
        "name": "Jelena Jovanovic",
        "paperCount": 2,
        "totalCitations": 99,
        "avgCitations": 50,
        "topPaper": {
          "pmid": "38691678",
          "title": "Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.",
          "year": "2024",
          "citationCount": 50
        },
        "role": "Active Contributor"
      },
      {
        "name": "S. Freeman",
        "paperCount": 2,
        "totalCitations": 99,
        "avgCitations": 50,
        "topPaper": {
          "pmid": "38691678",
          "title": "Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.",
          "year": "2024",
          "citationCount": 50
        },
        "role": "Active Contributor"
      },
      {
        "name": "A. Gilkes",
        "paperCount": 2,
        "totalCitations": 99,
        "avgCitations": 50,
        "topPaper": {
          "pmid": "38691678",
          "title": "Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.",
          "year": "2024",
          "citationCount": 50
        },
        "role": "Active Contributor"
      },
      {
        "name": "Manohursingh Runglall",
        "paperCount": 2,
        "totalCitations": 99,
        "avgCitations": 50,
        "topPaper": {
          "pmid": "38691678",
          "title": "Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.",
          "year": "2024",
          "citationCount": 50
        },
        "role": "Active Contributor"
      },
      {
        "name": "Ian Thomas",
        "paperCount": 2,
        "totalCitations": 99,
        "avgCitations": 50,
        "topPaper": {
          "pmid": "38691678",
          "title": "Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.",
          "year": "2024",
          "citationCount": 50
        },
        "role": "Active Contributor"
      },
      {
        "name": "S. Johnson",
        "paperCount": 2,
        "totalCitations": 99,
        "avgCitations": 50,
        "topPaper": {
          "pmid": "38691678",
          "title": "Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.",
          "year": "2024",
          "citationCount": 50
        },
        "role": "Active Contributor"
      }
    ],
    "recommendedPapers": [],
    "totalPapersUsed": 9,
    "evidenceSummary": {
      "totalItems": 17,
      "papersWithEvidence": 7,
      "topItems": [
        {
          "pmid": "38691678",
          "label": "n=1357",
          "context": "(National Cancer Research Institute [NCRI] AML17 and AML19, n = 1357) to delineate the impact of baseline molecular and clinical"
        },
        {
          "pmid": "39180903",
          "label": "p=0.52",
          "context": "57.8 % (n=11) in 19 patients with prior FLT3 TKI exposure (P=0.52). At the end of the first cycle, the median time to ANC > 0"
        },
        {
          "pmid": "39180903",
          "label": "p=0.79",
          "context": "nts without and with prior FLT3 TKI exposure, respectively (P=0.79). The estimated 2-year OS was 62 % in 19 (65.5 %) patients"
        },
        {
          "pmid": "39180903",
          "label": "p=0.03",
          "context": "rapy and 37 % in 10 patients who did not receive allo-HSCT (P=0.03). In conclusion, triplet therapy with gilteritinib, VEN, an"
        },
        {
          "pmid": "39180903",
          "label": "n=18",
          "context": "dified composite complete remission (mCRc) rate was 62.1 % (n = 18; CR, 4/29,13.8 %; CRi, 6/29, 20.7 %; MLFS, 8/29, 27.6 %). A"
        },
        {
          "pmid": "39180903",
          "label": "n=17",
          "context": "18 patients achieved mCRc, FLT3-PCR negativity was 94.4 % (n=17), and flow-cytometry negativity was 77.7 % (n=14). The mCRc"
        },
        {
          "pmid": "38364112",
          "label": "737 patients",
          "context": "hain reaction after 2 courses of induction chemotherapy. Of 737 patients achieving remission, MRD was positive in 19%. CR1-allo was"
        },
        {
          "pmid": "40332046",
          "label": "84 patients",
          "context": "te (ORR) and duration of response. As of 18 September 2024, 84 patients received ≥1 dose of revumenib. Median age was 63 years; 1 p"
        },
        {
          "pmid": "40662375",
          "label": "p<0.0001",
          "context": "MT3A mutation and tended to be related to normal karyotype (p < 0.0001, p = 0.0001, 0.019, and 0.062). Furthermore, none of the KM"
        },
        {
          "pmid": "40662375",
          "label": "p=0.0001",
          "context": "n and tended to be related to normal karyotype (p < 0.0001, p = 0.0001, 0.019, and 0.062). Furthermore, none of the KMT2A-PTD (+)"
        },
        {
          "pmid": "40662375",
          "label": "p=0.0005",
          "context": ") patients had NPM1 mutation, CEBPA bZIP in-frame mutation (p = 0.0005 and 0.0009), and none of them had KMT2A-rearrangement and o"
        },
        {
          "pmid": "40662375",
          "label": "p=0.16",
          "context": "one of them had KMT2A-rearrangement and other gene fusions (p = 0.16). As a result, all KMT2A-PTD (+) patients were categorized"
        },
        {
          "pmid": "40662375",
          "label": "p>0.05",
          "context": "ercentage of bone marrow blast cells, and FAB subtypes (all p > 0.05). KMT2A-PTD had no effect on complete remission achievement"
        },
        {
          "pmid": "40396900",
          "label": "HR=1.89",
          "context": "bined with VEN. AML genetics and monocytic differentiation (HR = 1.89; 95% confidence interval, 1.35-2.66; P < 0.001) in NPM1 wil"
        },
        {
          "pmid": "40396900",
          "label": "p<0.001",
          "context": "erentiation (HR = 1.89; 95% confidence interval, 1.35-2.66; P < 0.001) in NPM1 wild-type cases correlated with an increased risk"
        },
        {
          "pmid": "40396900",
          "label": "678 patients",
          "context": "ltimodal, multicenter, international analysis, inclusive of 678 patients, comprehensively characterized the prognostic role of monoc"
        },
        {
          "pmid": "40829168",
          "label": "374 patients",
          "context": "of AML. In this study, we leveraged a multiomics cohort of 374 patients newly diagnosed with AML, integrating proteome, phosphoprot"
        }
      ]
    },
    "evidenceLedger": {
      "summary": {
        "totalItems": 17,
        "papersWithEvidence": 7,
        "topItems": [
          {
            "pmid": "38691678",
            "label": "n=1357",
            "context": "(National Cancer Research Institute [NCRI] AML17 and AML19, n = 1357) to delineate the impact of baseline molecular and clinical"
          },
          {
            "pmid": "39180903",
            "label": "p=0.52",
            "context": "57.8 % (n=11) in 19 patients with prior FLT3 TKI exposure (P=0.52). At the end of the first cycle, the median time to ANC > 0"
          },
          {
            "pmid": "39180903",
            "label": "p=0.79",
            "context": "nts without and with prior FLT3 TKI exposure, respectively (P=0.79). The estimated 2-year OS was 62 % in 19 (65.5 %) patients"
          },
          {
            "pmid": "39180903",
            "label": "p=0.03",
            "context": "rapy and 37 % in 10 patients who did not receive allo-HSCT (P=0.03). In conclusion, triplet therapy with gilteritinib, VEN, an"
          },
          {
            "pmid": "39180903",
            "label": "n=18",
            "context": "dified composite complete remission (mCRc) rate was 62.1 % (n = 18; CR, 4/29,13.8 %; CRi, 6/29, 20.7 %; MLFS, 8/29, 27.6 %). A"
          },
          {
            "pmid": "39180903",
            "label": "n=17",
            "context": "18 patients achieved mCRc, FLT3-PCR negativity was 94.4 % (n=17), and flow-cytometry negativity was 77.7 % (n=14). The mCRc"
          },
          {
            "pmid": "38364112",
            "label": "737 patients",
            "context": "hain reaction after 2 courses of induction chemotherapy. Of 737 patients achieving remission, MRD was positive in 19%. CR1-allo was"
          },
          {
            "pmid": "40332046",
            "label": "84 patients",
            "context": "te (ORR) and duration of response. As of 18 September 2024, 84 patients received ≥1 dose of revumenib. Median age was 63 years; 1 p"
          },
          {
            "pmid": "40662375",
            "label": "p<0.0001",
            "context": "MT3A mutation and tended to be related to normal karyotype (p < 0.0001, p = 0.0001, 0.019, and 0.062). Furthermore, none of the KM"
          },
          {
            "pmid": "40662375",
            "label": "p=0.0001",
            "context": "n and tended to be related to normal karyotype (p < 0.0001, p = 0.0001, 0.019, and 0.062). Furthermore, none of the KMT2A-PTD (+)"
          },
          {
            "pmid": "40662375",
            "label": "p=0.0005",
            "context": ") patients had NPM1 mutation, CEBPA bZIP in-frame mutation (p = 0.0005 and 0.0009), and none of them had KMT2A-rearrangement and o"
          },
          {
            "pmid": "40662375",
            "label": "p=0.16",
            "context": "one of them had KMT2A-rearrangement and other gene fusions (p = 0.16). As a result, all KMT2A-PTD (+) patients were categorized"
          },
          {
            "pmid": "40662375",
            "label": "p>0.05",
            "context": "ercentage of bone marrow blast cells, and FAB subtypes (all p > 0.05). KMT2A-PTD had no effect on complete remission achievement"
          },
          {
            "pmid": "40396900",
            "label": "HR=1.89",
            "context": "bined with VEN. AML genetics and monocytic differentiation (HR = 1.89; 95% confidence interval, 1.35-2.66; P < 0.001) in NPM1 wil"
          },
          {
            "pmid": "40396900",
            "label": "p<0.001",
            "context": "erentiation (HR = 1.89; 95% confidence interval, 1.35-2.66; P < 0.001) in NPM1 wild-type cases correlated with an increased risk"
          },
          {
            "pmid": "40396900",
            "label": "678 patients",
            "context": "ltimodal, multicenter, international analysis, inclusive of 678 patients, comprehensively characterized the prognostic role of monoc"
          },
          {
            "pmid": "40829168",
            "label": "374 patients",
            "context": "of AML. In this study, we leveraged a multiomics cohort of 374 patients newly diagnosed with AML, integrating proteome, phosphoprot"
          }
        ]
      },
      "papers": [
        {
          "pmid": "39115831",
          "title": "Contemporary Management of Acute Myeloid Leukemia: A Review.",
          "journal": "JAMA oncology",
          "year": "2024",
          "citationCount": 44,
          "influentialCitationCount": 2,
          "isReview": true,
          "studyType": "review",
          "studyDesign": null,
          "sampleSize": null,
          "sampleSizeText": null,
          "openAccessUrl": null,
          "evidencePolarity": "neutral",
          "evidenceSignals": {
            "supportHits": 0,
            "contradictHits": 0
          },
          "contradictionTags": [],
          "contradictionSummary": null,
          "journalTier": "tier2",
          "trialPhase": null,
          "isRetracted": false,
          "evidenceItems": [],
          "evidenceCount": 0,
          "evidenceScore": 3.71,
          "evidenceScoreComponents": {
            "citations": 1.98,
            "influential": 0.43,
            "sampleSize": 0,
            "evidenceItems": 0,
            "evidenceSignals": 0,
            "recency": 0.35,
            "studyType": 0.6,
            "studyDesign": 0,
            "polarity": 0,
            "journalTier": 0.35,
            "trialPhase": 0,
            "retraction": 0
          }
        },
        {
          "pmid": "40615295",
          "title": "Advances in menin inhibition in acute myeloid leukemia.",
          "journal": "Trends in cancer",
          "year": "2025",
          "citationCount": 3,
          "influentialCitationCount": 0,
          "isReview": true,
          "studyType": "review",
          "studyDesign": null,
          "sampleSize": null,
          "sampleSizeText": null,
          "openAccessUrl": null,
          "evidencePolarity": "support",
          "evidenceSignals": {
            "supportHits": 3,
            "contradictHits": 0
          },
          "contradictionTags": [],
          "contradictionSummary": null,
          "journalTier": "tier3",
          "trialPhase": null,
          "isRetracted": false,
          "evidenceItems": [],
          "evidenceCount": 0,
          "evidenceScore": 2.82,
          "evidenceScoreComponents": {
            "citations": 0.72,
            "influential": 0,
            "sampleSize": 0,
            "evidenceItems": 0,
            "evidenceSignals": 0.6,
            "recency": 0.35,
            "studyType": 0.6,
            "studyDesign": 0,
            "polarity": 0.4,
            "journalTier": 0.15,
            "trialPhase": 0,
            "retraction": 0
          }
        },
        {
          "pmid": "39195279",
          "title": "Common Driver Mutations in AML: Biological Impact, Clinical Considerations, and Treatment Strategies.",
          "journal": "Cells",
          "year": "2024",
          "citationCount": 15,
          "influentialCitationCount": 2,
          "isReview": true,
          "studyType": "review",
          "studyDesign": null,
          "sampleSize": null,
          "sampleSizeText": null,
          "openAccessUrl": "https://doi.org/10.3390/cells13161392",
          "evidencePolarity": "neutral",
          "evidenceSignals": {
            "supportHits": 0,
            "contradictHits": 0
          },
          "contradictionTags": [],
          "contradictionSummary": null,
          "journalTier": "tier1",
          "trialPhase": null,
          "isRetracted": false,
          "evidenceItems": [],
          "evidenceCount": 0,
          "evidenceScore": 3.42,
          "evidenceScoreComponents": {
            "citations": 1.44,
            "influential": 0.43,
            "sampleSize": 0,
            "evidenceItems": 0,
            "evidenceSignals": 0,
            "recency": 0.35,
            "studyType": 0.6,
            "studyDesign": 0,
            "polarity": 0,
            "journalTier": 0.6,
            "trialPhase": 0,
            "retraction": 0
          }
        },
        {
          "pmid": "39558390",
          "title": "Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead.",
          "journal": "Journal of hematology & oncology",
          "year": "2024",
          "citationCount": 17,
          "influentialCitationCount": 0,
          "isReview": true,
          "studyType": "review",
          "studyDesign": null,
          "sampleSize": null,
          "sampleSizeText": null,
          "openAccessUrl": null,
          "evidencePolarity": "neutral",
          "evidenceSignals": {
            "supportHits": 0,
            "contradictHits": 0
          },
          "contradictionTags": [],
          "contradictionSummary": null,
          "journalTier": "tier3",
          "trialPhase": null,
          "isRetracted": false,
          "evidenceItems": [],
          "evidenceCount": 0,
          "evidenceScore": 2.61,
          "evidenceScoreComponents": {
            "citations": 1.51,
            "influential": 0,
            "sampleSize": 0,
            "evidenceItems": 0,
            "evidenceSignals": 0,
            "recency": 0.35,
            "studyType": 0.6,
            "studyDesign": 0,
            "polarity": 0,
            "journalTier": 0.15,
            "trialPhase": 0,
            "retraction": 0
          }
        },
        {
          "pmid": "38969930",
          "title": "DNMT3A-R882: a mutation with many paradoxes.",
          "journal": "Annals of hematology",
          "year": "2024",
          "citationCount": 1,
          "influentialCitationCount": 0,
          "isReview": true,
          "studyType": "review",
          "studyDesign": null,
          "sampleSize": null,
          "sampleSizeText": null,
          "openAccessUrl": null,
          "evidencePolarity": "support",
          "evidenceSignals": {
            "supportHits": 1,
            "contradictHits": 0
          },
          "contradictionTags": [],
          "contradictionSummary": null,
          "journalTier": "tier3",
          "trialPhase": null,
          "isRetracted": false,
          "evidenceItems": [],
          "evidenceCount": 0,
          "evidenceScore": 2.06,
          "evidenceScoreComponents": {
            "citations": 0.36,
            "influential": 0,
            "sampleSize": 0,
            "evidenceItems": 0,
            "evidenceSignals": 0.2,
            "recency": 0.35,
            "studyType": 0.6,
            "studyDesign": 0,
            "polarity": 0.4,
            "journalTier": 0.15,
            "trialPhase": 0,
            "retraction": 0
          }
        },
        {
          "pmid": "38651453",
          "title": "A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia.",
          "journal": "Hematology reports",
          "year": "2024",
          "citationCount": 45,
          "influentialCitationCount": 1,
          "isReview": true,
          "studyType": "review",
          "studyDesign": null,
          "sampleSize": null,
          "sampleSizeText": null,
          "openAccessUrl": "https://www.mdpi.com/2038-8330/16/2/24/pdf?version=1713434481",
          "evidencePolarity": "support",
          "evidenceSignals": {
            "supportHits": 1,
            "contradictHits": 0
          },
          "contradictionTags": [],
          "contradictionSummary": null,
          "journalTier": "tier3",
          "trialPhase": "I",
          "isRetracted": false,
          "evidenceItems": [],
          "evidenceCount": 0,
          "evidenceScore": 4.17,
          "evidenceScoreComponents": {
            "citations": 2,
            "influential": 0.27,
            "sampleSize": 0,
            "evidenceItems": 0,
            "evidenceSignals": 0.2,
            "recency": 0.35,
            "studyType": 0.6,
            "studyDesign": 0,
            "polarity": 0.4,
            "journalTier": 0.15,
            "trialPhase": 0.2,
            "retraction": 0
          }
        },
        {
          "pmid": "39719041",
          "title": "Menin inhibitors in the treatment of acute myeloid leukemia.",
          "journal": "Blood",
          "year": "2025",
          "citationCount": 12,
          "influentialCitationCount": 0,
          "isReview": true,
          "studyType": "review",
          "studyDesign": null,
          "sampleSize": null,
          "sampleSizeText": null,
          "openAccessUrl": null,
          "evidencePolarity": "neutral",
          "evidenceSignals": {
            "supportHits": 0,
            "contradictHits": 0
          },
          "contradictionTags": [],
          "contradictionSummary": null,
          "journalTier": "tier2",
          "trialPhase": null,
          "isRetracted": false,
          "evidenceItems": [],
          "evidenceCount": 0,
          "evidenceScore": 2.64,
          "evidenceScoreComponents": {
            "citations": 1.34,
            "influential": 0,
            "sampleSize": 0,
            "evidenceItems": 0,
            "evidenceSignals": 0,
            "recency": 0.35,
            "studyType": 0.6,
            "studyDesign": 0,
            "polarity": 0,
            "journalTier": 0.35,
            "trialPhase": 0,
            "retraction": 0
          }
        },
        {
          "pmid": "38691678",
          "title": "Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.",
          "journal": "Blood",
          "year": "2024",
          "citationCount": 50,
          "influentialCitationCount": 1,
          "isReview": false,
          "studyType": "mixed",
          "studyDesign": null,
          "sampleSize": null,
          "sampleSizeText": null,
          "openAccessUrl": null,
          "evidencePolarity": "mixed",
          "evidenceSignals": {
            "supportHits": 2,
            "contradictHits": 1
          },
          "contradictionTags": [
            "heterogeneity"
          ],
          "contradictionSummary": "Heterogeneity",
          "journalTier": "tier2",
          "trialPhase": null,
          "isRetracted": false,
          "evidenceItems": [
            {
              "pmid": "38691678",
              "label": "n=1357",
              "context": "(National Cancer Research Institute [NCRI] AML17 and AML19, n = 1357) to delineate the impact of baseline molecular and clinical"
            }
          ],
          "evidenceCount": 1,
          "evidenceScore": 4.32,
          "evidenceScoreComponents": {
            "citations": 2.05,
            "influential": 0.27,
            "sampleSize": 0,
            "evidenceItems": 0.35,
            "evidenceSignals": 0.05,
            "recency": 0.35,
            "studyType": 0.8,
            "studyDesign": 0,
            "polarity": 0.1,
            "journalTier": 0.35,
            "trialPhase": 0,
            "retraction": 0
          }
        },
        {
          "pmid": "39180903",
          "title": "Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3 acute myeloid leukemia.",
          "journal": "Leukemia research",
          "year": "2024",
          "citationCount": 7,
          "influentialCitationCount": 0,
          "isReview": false,
          "studyType": "mixed",
          "studyDesign": null,
          "sampleSize": 19,
          "sampleSizeText": "19 patients",
          "openAccessUrl": null,
          "evidencePolarity": "neutral",
          "evidenceSignals": {
            "supportHits": 0,
            "contradictHits": 0
          },
          "contradictionTags": [],
          "contradictionSummary": null,
          "journalTier": "tier3",
          "trialPhase": null,
          "isRetracted": false,
          "evidenceItems": [
            {
              "pmid": "39180903",
              "label": "p=0.52",
              "context": "57.8 % (n=11) in 19 patients with prior FLT3 TKI exposure (P=0.52). At the end of the first cycle, the median time to ANC > 0"
            },
            {
              "pmid": "39180903",
              "label": "p=0.79",
              "context": "nts without and with prior FLT3 TKI exposure, respectively (P=0.79). The estimated 2-year OS was 62 % in 19 (65.5 %) patients"
            },
            {
              "pmid": "39180903",
              "label": "p=0.03",
              "context": "rapy and 37 % in 10 patients who did not receive allo-HSCT (P=0.03). In conclusion, triplet therapy with gilteritinib, VEN, an"
            }
          ],
          "evidenceCount": 5,
          "evidenceScore": 5.11,
          "evidenceScoreComponents": {
            "citations": 1.08,
            "influential": 0,
            "sampleSize": 0.98,
            "evidenceItems": 1.75,
            "evidenceSignals": 0,
            "recency": 0.35,
            "studyType": 0.8,
            "studyDesign": 0,
            "polarity": 0,
            "journalTier": 0.15,
            "trialPhase": 0,
            "retraction": 0
          }
        },
        {
          "pmid": "38364112",
          "title": "Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.",
          "journal": "Blood",
          "year": "2024",
          "citationCount": 49,
          "influentialCitationCount": 2,
          "isReview": false,
          "studyType": "mixed",
          "studyDesign": null,
          "sampleSize": 737,
          "sampleSizeText": "737 patients",
          "openAccessUrl": null,
          "evidencePolarity": "neutral",
          "evidenceSignals": {
            "supportHits": 0,
            "contradictHits": 0
          },
          "contradictionTags": [],
          "contradictionSummary": null,
          "journalTier": "tier2",
          "trialPhase": null,
          "isRetracted": false,
          "evidenceItems": [
            {
              "pmid": "38364112",
              "label": "737 patients",
              "context": "hain reaction after 2 courses of induction chemotherapy. Of 737 patients achieving remission, MRD was positive in 19%. CR1-allo was"
            }
          ],
          "evidenceCount": 1,
          "evidenceScore": 6.47,
          "evidenceScoreComponents": {
            "citations": 2.04,
            "influential": 0.43,
            "sampleSize": 2.15,
            "evidenceItems": 0.35,
            "evidenceSignals": 0,
            "recency": 0.35,
            "studyType": 0.8,
            "studyDesign": 0,
            "polarity": 0,
            "journalTier": 0.35,
            "trialPhase": 0,
            "retraction": 0
          }
        },
        {
          "pmid": "40332046",
          "title": "Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.",
          "journal": "Blood",
          "year": "2025",
          "citationCount": 17,
          "influentialCitationCount": 1,
          "isReview": false,
          "studyType": "mixed",
          "studyDesign": null,
          "sampleSize": 84,
          "sampleSizeText": "84 patients",
          "openAccessUrl": null,
          "evidencePolarity": "neutral",
          "evidenceSignals": {
            "supportHits": 0,
            "contradictHits": 0
          },
          "contradictionTags": [],
          "contradictionSummary": null,
          "journalTier": "tier2",
          "trialPhase": "II",
          "isRetracted": false,
          "evidenceItems": [
            {
              "pmid": "40332046",
              "label": "84 patients",
              "context": "te (ORR) and duration of response. As of 18 September 2024, 84 patients received ≥1 dose of revumenib. Median age was 63 years; 1 p"
            }
          ],
          "evidenceCount": 1,
          "evidenceScore": 5.42,
          "evidenceScoreComponents": {
            "citations": 1.51,
            "influential": 0.27,
            "sampleSize": 1.45,
            "evidenceItems": 0.35,
            "evidenceSignals": 0,
            "recency": 0.35,
            "studyType": 0.8,
            "studyDesign": 0,
            "polarity": 0,
            "journalTier": 0.35,
            "trialPhase": 0.35,
            "retraction": 0
          }
        },
        {
          "pmid": "40662375",
          "title": "The Characteristics and Outcomes of Adult Acute Myeloid Leukemia Patients With KMT2A-Partial Tandem Duplication.",
          "journal": "International journal of laboratory hematology",
          "year": "2025",
          "citationCount": 1,
          "influentialCitationCount": 0,
          "isReview": false,
          "studyType": "mixed",
          "studyDesign": "cohort",
          "sampleSize": null,
          "sampleSizeText": null,
          "openAccessUrl": null,
          "evidencePolarity": "contradict",
          "evidenceSignals": {
            "supportHits": 0,
            "contradictHits": 1
          },
          "contradictionTags": [
            "no_association",
            "statistical",
            "population"
          ],
          "contradictionSummary": "No association, Non-significant statistics, Population-specific",
          "journalTier": "tier3",
          "trialPhase": null,
          "isRetracted": false,
          "evidenceItems": [
            {
              "pmid": "40662375",
              "label": "p<0.0001",
              "context": "MT3A mutation and tended to be related to normal karyotype (p < 0.0001, p = 0.0001, 0.019, and 0.062). Furthermore, none of the KM"
            },
            {
              "pmid": "40662375",
              "label": "p=0.0001",
              "context": "n and tended to be related to normal karyotype (p < 0.0001, p = 0.0001, 0.019, and 0.062). Furthermore, none of the KMT2A-PTD (+)"
            },
            {
              "pmid": "40662375",
              "label": "p=0.0005",
              "context": ") patients had NPM1 mutation, CEBPA bZIP in-frame mutation (p = 0.0005 and 0.0009), and none of them had KMT2A-rearrangement and o"
            }
          ],
          "evidenceCount": 5,
          "evidenceScore": 2.96,
          "evidenceScoreComponents": {
            "citations": 0.36,
            "influential": 0,
            "sampleSize": 0,
            "evidenceItems": 1.75,
            "evidenceSignals": -0.35,
            "recency": 0.35,
            "studyType": 0.8,
            "studyDesign": 0.45,
            "polarity": -0.55,
            "journalTier": 0.15,
            "trialPhase": 0,
            "retraction": 0
          }
        },
        {
          "pmid": "40396900",
          "title": "Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study.",
          "journal": "Blood cancer discovery",
          "year": "2025",
          "citationCount": 4,
          "influentialCitationCount": 0,
          "isReview": false,
          "studyType": "mixed",
          "studyDesign": null,
          "sampleSize": 678,
          "sampleSizeText": "678 patients",
          "openAccessUrl": null,
          "evidencePolarity": "support",
          "evidenceSignals": {
            "supportHits": 1,
            "contradictHits": 0
          },
          "contradictionTags": [],
          "contradictionSummary": null,
          "journalTier": "tier2",
          "trialPhase": null,
          "isRetracted": false,
          "evidenceItems": [
            {
              "pmid": "40396900",
              "label": "HR=1.89",
              "context": "bined with VEN. AML genetics and monocytic differentiation (HR = 1.89; 95% confidence interval, 1.35-2.66; P < 0.001) in NPM1 wil"
            },
            {
              "pmid": "40396900",
              "label": "p<0.001",
              "context": "erentiation (HR = 1.89; 95% confidence interval, 1.35-2.66; P < 0.001) in NPM1 wild-type cases correlated with an increased risk"
            },
            {
              "pmid": "40396900",
              "label": "678 patients",
              "context": "ltimodal, multicenter, international analysis, inclusive of 678 patients, comprehensively characterized the prognostic role of monoc"
            }
          ],
          "evidenceCount": 3,
          "evidenceScore": 6.11,
          "evidenceScoreComponents": {
            "citations": 0.84,
            "influential": 0,
            "sampleSize": 2.12,
            "evidenceItems": 1.05,
            "evidenceSignals": 0.2,
            "recency": 0.35,
            "studyType": 0.8,
            "studyDesign": 0,
            "polarity": 0.4,
            "journalTier": 0.35,
            "trialPhase": 0,
            "retraction": 0
          }
        },
        {
          "pmid": "40829168",
          "title": "Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.",
          "journal": "Blood",
          "year": "2025",
          "citationCount": 0,
          "influentialCitationCount": 0,
          "isReview": false,
          "studyType": "mixed",
          "studyDesign": "cohort",
          "sampleSize": 374,
          "sampleSizeText": "374 patients",
          "openAccessUrl": null,
          "evidencePolarity": "support",
          "evidenceSignals": {
            "supportHits": 1,
            "contradictHits": 0
          },
          "contradictionTags": [],
          "contradictionSummary": null,
          "journalTier": "tier2",
          "trialPhase": null,
          "isRetracted": false,
          "evidenceItems": [
            {
              "pmid": "40829168",
              "label": "374 patients",
              "context": "of AML. In this study, we leveraged a multiomics cohort of 374 patients newly diagnosed with AML, integrating proteome, phosphoprot"
            }
          ],
          "evidenceCount": 1,
          "evidenceScore": 4.83,
          "evidenceScoreComponents": {
            "citations": 0,
            "influential": 0,
            "sampleSize": 1.93,
            "evidenceItems": 0.35,
            "evidenceSignals": 0.2,
            "recency": 0.35,
            "studyType": 0.8,
            "studyDesign": 0.45,
            "polarity": 0.4,
            "journalTier": 0.35,
            "trialPhase": 0,
            "retraction": 0
          }
        }
      ],
      "insightLinks": {
        "pathways": [
          {
            "id": "pathway-0",
            "label": "FLT3 Signaling",
            "citations": [
              "PMID:39195279",
              "PMID:39558390"
            ],
            "pmids": [
              "39195279",
              "39558390"
            ],
            "supportingPmids": [],
            "contradictingPmids": [],
            "mixedPmids": [],
            "evidenceSnippets": [],
            "evidenceStatus": "unverified",
            "quantitativeData": "n=1357; p=0.03 for survival differences in FLT3-ITD positive patients.",
            "quantitativeWarning": "Quantitative data not supported by extracted abstract evidence",
            "quantEvidence": [],
            "trustRationale": "No direct support in 2 cited papers.",
            "evidenceBadge": {
              "label": "Evidence sparse",
              "level": "sparse",
              "score": 0,
              "supportCount": 0,
              "contradictCount": 0,
              "detail": "No supporting papers linked"
            },
            "provenance": {
              "supportingPmids": [],
              "contradictingPmids": [],
              "mixedPmids": [],
              "trustRationale": "No direct support in 2 cited papers.",
              "evidenceBadge": {
                "label": "Evidence sparse",
                "level": "sparse",
                "score": 0,
                "supportCount": 0,
                "contradictCount": 0,
                "detail": "No supporting papers linked"
              }
            }
          },
          {
            "id": "pathway-1",
            "label": "DNA methylation",
            "citations": [
              "PMID:38969930",
              "PMID:38651453"
            ],
            "pmids": [
              "38969930",
              "38651453"
            ],
            "supportingPmids": [
              "38969930",
              "38651453"
            ],
            "contradictingPmids": [],
            "mixedPmids": [],
            "evidenceSnippets": [],
            "evidenceStatus": "unverified",
            "quantitativeData": "n=1357; HR=1.89 for poor outcomes associated with DNMT3A mutations.",
            "quantitativeWarning": "Quantitative data not supported by extracted abstract evidence",
            "quantEvidence": [],
            "trustRationale": "Supported by 2/2 papers; top support PMID:38651453 (TIER3, Phase I, review, score 4.17).",
            "evidenceBadge": {
              "label": "Preliminary evidence",
              "level": "preliminary",
              "score": 0.52,
              "supportCount": 2,
              "contradictCount": 0,
              "detail": "Support 2 • Contradict 0 • Top journal TIER3 • Preclinical/unknown"
            },
            "provenance": {
              "supportingPmids": [
                "38969930",
                "38651453"
              ],
              "contradictingPmids": [],
              "mixedPmids": [],
              "trustRationale": "Supported by 2/2 papers; top support PMID:38651453 (TIER3, Phase I, review, score 4.17).",
              "evidenceBadge": {
                "label": "Preliminary evidence",
                "level": "preliminary",
                "score": 0.52,
                "supportCount": 2,
                "contradictCount": 0,
                "detail": "Support 2 • Contradict 0 • Top journal TIER3 • Preclinical/unknown"
              }
            }
          },
          {
            "id": "pathway-2",
            "label": "Cysteine and methionine metabolism",
            "citations": [
              "PMID:40615295",
              "PMID:39115831"
            ],
            "pmids": [
              "40615295",
              "39115831"
            ],
            "supportingPmids": [
              "40615295"
            ],
            "contradictingPmids": [],
            "mixedPmids": [],
            "evidenceSnippets": [],
            "evidenceStatus": "unverified",
            "quantitativeData": "Not reported in abstracts",
            "quantEvidence": [],
            "trustRationale": "Supported by 1/2 papers; top support PMID:40615295 (TIER3, review, score 2.82).",
            "evidenceBadge": {
              "label": "Preliminary evidence",
              "level": "preliminary",
              "score": 0.49,
              "supportCount": 1,
              "contradictCount": 0,
              "detail": "Support 1 • Contradict 0 • Top journal TIER3 • Preclinical/unknown"
            },
            "provenance": {
              "supportingPmids": [
                "40615295"
              ],
              "contradictingPmids": [],
              "mixedPmids": [],
              "trustRationale": "Supported by 1/2 papers; top support PMID:40615295 (TIER3, review, score 2.82).",
              "evidenceBadge": {
                "label": "Preliminary evidence",
                "level": "preliminary",
                "score": 0.49,
                "supportCount": 1,
                "contradictCount": 0,
                "detail": "Support 1 • Contradict 0 • Top journal TIER3 • Preclinical/unknown"
              }
            }
          }
        ],
        "strategies": [
          {
            "id": "strategy-0",
            "label": "Menin inhibition",
            "citations": [
              "PMID:40615295",
              "PMID:38651453"
            ],
            "pmids": [
              "40615295",
              "38651453"
            ],
            "supportingPmids": [
              "40615295",
              "38651453"
            ],
            "contradictingPmids": [],
            "mixedPmids": [],
            "evidenceSnippets": [],
            "evidenceStatus": "unverified",
            "quantitativeData": "Not reported in abstracts",
            "quantEvidence": [],
            "trustRationale": "Supported by 2/2 papers; top support PMID:38651453 (TIER3, Phase I, review, score 4.17).",
            "evidenceBadge": {
              "label": "Preliminary evidence",
              "level": "preliminary",
              "score": 0.53,
              "supportCount": 2,
              "contradictCount": 0,
              "detail": "Support 2 • Contradict 0 • Top journal TIER3 • Preclinical/unknown"
            },
            "provenance": {
              "supportingPmids": [
                "40615295",
                "38651453"
              ],
              "contradictingPmids": [],
              "mixedPmids": [],
              "trustRationale": "Supported by 2/2 papers; top support PMID:38651453 (TIER3, Phase I, review, score 4.17).",
              "evidenceBadge": {
                "label": "Preliminary evidence",
                "level": "preliminary",
                "score": 0.53,
                "supportCount": 2,
                "contradictCount": 0,
                "detail": "Support 2 • Contradict 0 • Top journal TIER3 • Preclinical/unknown"
              }
            }
          },
          {
            "id": "strategy-1",
            "label": "FLT3 inhibition",
            "citations": [
              "PMID:39180903",
              "PMID:39719041"
            ],
            "pmids": [
              "39180903",
              "39719041"
            ],
            "supportingPmids": [],
            "contradictingPmids": [],
            "mixedPmids": [],
            "evidenceSnippets": [
              "[object Object]",
              "[object Object]"
            ],
            "evidenceStatus": "grounded",
            "quantitativeData": "p=0.03 for survival benefit in FLT3-ITD positive patients.",
            "quantEvidence": [
              {
                "pmid": "39180903",
                "label": "p=0.52",
                "context": "57.8 % (n=11) in 19 patients with prior FLT3 TKI exposure (P=0.52). At the end of the first cycle, the median time to ANC > 0"
              },
              {
                "pmid": "39180903",
                "label": "p=0.79",
                "context": "nts without and with prior FLT3 TKI exposure, respectively (P=0.79). The estimated 2-year OS was 62 % in 19 (65.5 %) patients"
              },
              {
                "pmid": "39180903",
                "label": "p=0.03",
                "context": "rapy and 37 % in 10 patients who did not receive allo-HSCT (P=0.03). In conclusion, triplet therapy with gilteritinib, VEN, an"
              }
            ],
            "trustRationale": "No direct support in 2 cited papers.",
            "evidenceBadge": {
              "label": "Evidence sparse",
              "level": "sparse",
              "score": 0,
              "supportCount": 0,
              "contradictCount": 0,
              "detail": "No supporting papers linked"
            },
            "provenance": {
              "supportingPmids": [],
              "contradictingPmids": [],
              "mixedPmids": [],
              "trustRationale": "No direct support in 2 cited papers.",
              "evidenceBadge": {
                "label": "Evidence sparse",
                "level": "sparse",
                "score": 0,
                "supportCount": 0,
                "contradictCount": 0,
                "detail": "No supporting papers linked"
              }
            }
          },
          {
            "id": "hypothesis-0",
            "label": "Novel hypothesis: Targeting the interplay between DNMT3A mutations and metabolic pathways may enhance therapeutic efficacy in AML.",
            "citations": [
              "PMID:38969930",
              "PMID:38691678"
            ],
            "pmids": [
              "38969930",
              "38691678"
            ],
            "supportingPmids": [
              "38969930"
            ],
            "contradictingPmids": [],
            "mixedPmids": [
              "38691678"
            ],
            "evidenceSnippets": [],
            "evidenceStatus": "unverified",
            "quantEvidence": [
              {
                "pmid": "38691678",
                "label": "n=1357",
                "context": "(National Cancer Research Institute [NCRI] AML17 and AML19, n = 1357) to delineate the impact of baseline molecular and clinical"
              }
            ],
            "trustRationale": "Supported by 1/2 papers; top support PMID:38969930 (TIER3, review, score 2.06).",
            "evidenceBadge": {
              "label": "Preliminary evidence",
              "level": "preliminary",
              "score": 0.45,
              "supportCount": 1,
              "contradictCount": 0,
              "detail": "Support 1 • Contradict 0 • Top journal TIER3 • Preclinical/unknown"
            },
            "provenance": {
              "supportingPmids": [
                "38969930"
              ],
              "contradictingPmids": [],
              "mixedPmids": [
                "38691678"
              ],
              "trustRationale": "Supported by 1/2 papers; top support PMID:38969930 (TIER3, review, score 2.06).",
              "evidenceBadge": {
                "label": "Preliminary evidence",
                "level": "preliminary",
                "score": 0.45,
                "supportCount": 1,
                "contradictCount": 0,
                "detail": "Support 1 • Contradict 0 • Top journal TIER3 • Preclinical/unknown"
              }
            }
          }
        ],
        "topics": [
          {
            "id": "topic-0",
            "label": "Emerging therapeutic strategies targeting genetic mutations in AML.",
            "citations": [
              "PMID:39195279",
              "PMID:38651453"
            ],
            "pmids": [
              "39195279",
              "38651453"
            ],
            "supportingPmids": [
              "38651453"
            ],
            "contradictingPmids": [],
            "mixedPmids": [],
            "evidenceSnippets": [],
            "evidenceStatus": "unverified",
            "quantEvidence": [],
            "trustRationale": "Supported by 1/2 papers; top support PMID:38651453 (TIER3, Phase I, review, score 4.17).",
            "evidenceBadge": {
              "label": "Moderate confidence",
              "level": "moderate",
              "score": 0.58,
              "supportCount": 1,
              "contradictCount": 0,
              "detail": "Support 1 • Contradict 0 • Top journal TIER3 • Preclinical/unknown"
            },
            "provenance": {
              "supportingPmids": [
                "38651453"
              ],
              "contradictingPmids": [],
              "mixedPmids": [],
              "trustRationale": "Supported by 1/2 papers; top support PMID:38651453 (TIER3, Phase I, review, score 4.17).",
              "evidenceBadge": {
                "label": "Moderate confidence",
                "level": "moderate",
                "score": 0.58,
                "supportCount": 1,
                "contradictCount": 0,
                "detail": "Support 1 • Contradict 0 • Top journal TIER3 • Preclinical/unknown"
              }
            }
          }
        ]
      },
      "hypothesisLinks": [
        {
          "id": "1b58d2f52108e96e",
          "type": "drug_repurposing",
          "statement": "DAUNORUBICIN LIPOSOMAL may be repurposed to treat acute myeloid leukemia",
          "confidence": 0.8999999999999999,
          "evidenceStrength": 1,
          "pmids": [],
          "supportingPmids": [],
          "contradictingPmids": [],
          "mixedPmids": [],
          "evidenceSummary": [
            {
              "type": "target_overlap",
              "source": null,
              "weight": 0.817,
              "gene": "DNMT3A"
            },
            {
              "type": "target_overlap",
              "source": null,
              "weight": 0.809,
              "gene": "FLT3"
            },
            {
              "type": "target_overlap",
              "source": null,
              "weight": 0.656,
              "gene": "NPM1"
            },
            {
              "type": "target_overlap",
              "source": null,
              "weight": 0.809,
              "gene": "FLT3"
            }
          ],
          "quantEvidence": [],
          "trustRationale": "No linked papers for this claim.",
          "evidenceBadge": {
            "label": "Evidence sparse",
            "level": "sparse",
            "score": 0,
            "supportCount": 0,
            "contradictCount": 0,
            "detail": "No supporting papers linked"
          },
          "provenance": {
            "supportingPmids": [],
            "contradictingPmids": [],
            "mixedPmids": [],
            "trustRationale": "No linked papers for this claim.",
            "evidenceBadge": {
              "label": "Evidence sparse",
              "level": "sparse",
              "score": 0,
              "supportCount": 0,
              "contradictCount": 0,
              "detail": "No supporting papers linked"
            }
          }
        },
        {
          "id": "7022f99bce9e2693",
          "type": "drug_repurposing",
          "statement": "AZACITIDINE may be repurposed to treat acute myeloid leukemia",
          "confidence": 0.8671428571428571,
          "evidenceStrength": 1,
          "pmids": [],
          "supportingPmids": [],
          "contradictingPmids": [],
          "mixedPmids": [],
          "evidenceSummary": [
            {
              "type": "target_overlap",
              "source": null,
              "weight": 0.817,
              "gene": "DNMT3A"
            },
            {
              "type": "target_overlap",
              "source": null,
              "weight": 0.809,
              "gene": "FLT3"
            },
            {
              "type": "target_overlap",
              "source": null,
              "weight": 0.809,
              "gene": "FLT3"
            },
            {
              "type": "target_overlap",
              "source": null,
              "weight": 0.817,
              "gene": "DNMT3A"
            }
          ],
          "quantEvidence": [],
          "trustRationale": "No linked papers for this claim.",
          "evidenceBadge": {
            "label": "Evidence sparse",
            "level": "sparse",
            "score": 0,
            "supportCount": 0,
            "contradictCount": 0,
            "detail": "No supporting papers linked"
          },
          "provenance": {
            "supportingPmids": [],
            "contradictingPmids": [],
            "mixedPmids": [],
            "trustRationale": "No linked papers for this claim.",
            "evidenceBadge": {
              "label": "Evidence sparse",
              "level": "sparse",
              "score": 0,
              "supportCount": 0,
              "contradictCount": 0,
              "detail": "No supporting papers linked"
            }
          }
        },
        {
          "id": "4dfff9cdffee13df",
          "type": "drug_repurposing",
          "statement": "QUIZARTINIB may be repurposed to treat acute myeloid leukemia",
          "confidence": 0.8671428571428571,
          "evidenceStrength": 1,
          "pmids": [],
          "supportingPmids": [],
          "contradictingPmids": [],
          "mixedPmids": [],
          "evidenceSummary": [
            {
              "type": "target_overlap",
              "source": null,
              "weight": 0.817,
              "gene": "DNMT3A"
            },
            {
              "type": "target_overlap",
              "source": null,
              "weight": 0.809,
              "gene": "FLT3"
            },
            {
              "type": "target_overlap",
              "source": null,
              "weight": 0.809,
              "gene": "FLT3"
            },
            {
              "type": "target_overlap",
              "source": null,
              "weight": 0.817,
              "gene": "DNMT3A"
            }
          ],
          "quantEvidence": [],
          "trustRationale": "No linked papers for this claim.",
          "evidenceBadge": {
            "label": "Evidence sparse",
            "level": "sparse",
            "score": 0,
            "supportCount": 0,
            "contradictCount": 0,
            "detail": "No supporting papers linked"
          },
          "provenance": {
            "supportingPmids": [],
            "contradictingPmids": [],
            "mixedPmids": [],
            "trustRationale": "No linked papers for this claim.",
            "evidenceBadge": {
              "label": "Evidence sparse",
              "level": "sparse",
              "score": 0,
              "supportCount": 0,
              "contradictCount": 0,
              "detail": "No supporting papers linked"
            }
          }
        },
        {
          "id": "8ce069c910d80c86",
          "type": "drug_repurposing",
          "statement": "DECITABINE may be repurposed to treat acute myeloid leukemia",
          "confidence": 0.8671428571428571,
          "evidenceStrength": 1,
          "pmids": [],
          "supportingPmids": [],
          "contradictingPmids": [],
          "mixedPmids": [],
          "evidenceSummary": [
            {
              "type": "target_overlap",
              "source": null,
              "weight": 0.817,
              "gene": "DNMT3A"
            },
            {
              "type": "target_overlap",
              "source": null,
              "weight": 0.809,
              "gene": "FLT3"
            },
            {
              "type": "target_overlap",
              "source": null,
              "weight": 0.809,
              "gene": "FLT3"
            },
            {
              "type": "target_overlap",
              "source": null,
              "weight": 0.817,
              "gene": "DNMT3A"
            }
          ],
          "quantEvidence": [],
          "trustRationale": "No linked papers for this claim.",
          "evidenceBadge": {
            "label": "Evidence sparse",
            "level": "sparse",
            "score": 0,
            "supportCount": 0,
            "contradictCount": 0,
            "detail": "No supporting papers linked"
          },
          "provenance": {
            "supportingPmids": [],
            "contradictingPmids": [],
            "mixedPmids": [],
            "trustRationale": "No linked papers for this claim.",
            "evidenceBadge": {
              "label": "Evidence sparse",
              "level": "sparse",
              "score": 0,
              "supportCount": 0,
              "contradictCount": 0,
              "detail": "No supporting papers linked"
            }
          }
        },
        {
          "id": "8a7ff51eaf259620",
          "type": "drug_repurposing",
          "statement": "IDARUBICIN may be repurposed to treat acute myeloid leukemia",
          "confidence": 0.8671428571428571,
          "evidenceStrength": 1,
          "pmids": [],
          "supportingPmids": [],
          "contradictingPmids": [],
          "mixedPmids": [],
          "evidenceSummary": [
            {
              "type": "target_overlap",
              "source": null,
              "weight": 0.817,
              "gene": "DNMT3A"
            },
            {
              "type": "target_overlap",
              "source": null,
              "weight": 0.809,
              "gene": "FLT3"
            },
            {
              "type": "target_overlap",
              "source": null,
              "weight": 0.809,
              "gene": "FLT3"
            },
            {
              "type": "target_overlap",
              "source": null,
              "weight": 0.817,
              "gene": "DNMT3A"
            }
          ],
          "quantEvidence": [],
          "trustRationale": "No linked papers for this claim.",
          "evidenceBadge": {
            "label": "Evidence sparse",
            "level": "sparse",
            "score": 0,
            "supportCount": 0,
            "contradictCount": 0,
            "detail": "No supporting papers linked"
          },
          "provenance": {
            "supportingPmids": [],
            "contradictingPmids": [],
            "mixedPmids": [],
            "trustRationale": "No linked papers for this claim.",
            "evidenceBadge": {
              "label": "Evidence sparse",
              "level": "sparse",
              "score": 0,
              "supportCount": 0,
              "contradictCount": 0,
              "detail": "No supporting papers linked"
            }
          }
        }
      ]
    },
    "evidenceScorecard": {
      "papers": {
        "support": 13,
        "contradict": 1,
        "mixed": 1,
        "neutral": 15
      },
      "insights": {
        "total": 7,
        "withSupport": 5,
        "withContradictions": 0,
        "withMixed": 1,
        "withoutCitations": 0
      },
      "hypotheses": {
        "total": 5,
        "withSupport": 0,
        "withContradictions": 0,
        "withMixed": 0
      },
      "citationWarnings": 0,
      "consensus": {
        "supportWeight": 19.99,
        "contradictWeight": 2.96,
        "mixedWeight": 4.32,
        "totalWeight": 27.27,
        "consensusRatio": 0.73,
        "contentionRatio": 0.27,
        "netConsensus": 0.62,
        "consensusLabel": "Strong",
        "contentionLabel": "Moderate"
      }
    },
    "qualityMetrics": {
      "score": 86,
      "groundedRatio": 0.17,
      "groundedCount": 1,
      "insightCount": 6,
      "pathways": 3,
      "strategies": 2,
      "topics": 1,
      "hypotheses": 5,
      "papersUsed": 9,
      "evidenceItems": 17,
      "evidencePapers": 7,
      "sourcesAvailable": 13,
      "sourcesTotal": 16
    },
    "learningMemory": {
      "source": "knowledge-graph-cache",
      "pathways": [
        {
          "pathway": "undefined",
          "geneOverlap": [
            "FLT3",
            "NPM1",
            "DNMT3A"
          ],
          "confidence": "cached"
        }
      ],
      "message": "Instant results from previous analyses! (No API calls needed)"
    },
    "audience": "researcher",
    "audienceLabel": "Researcher-focused view",
    "generatedAtIso": "2026-01-15T21:16:39.285Z",
    "analysisTime": "46942ms",
    "modelConfig": {
      "aiModelUsed": "GPT-4o-mini",
      "modelTimeoutMs": 90000,
      "providers": {
        "openai": true,
        "deepseek": true,
        "gemini": false,
        "anthropic": true
      },
      "modelIds": {
        "openai": "gpt-4o-mini",
        "deepseek": "deepseek-chat",
        "gemini": "gemini-2.0-flash-exp",
        "anthropic": "claude-3-5-sonnet-latest"
      },
      "includeDrugs": true
    },
    "dataSource": {
      "genes": "Ensembl + ClinVar + UniProt + Gene Ontology",
      "pathways": "KEGG + Reactome v95",
      "literature": "PubMed + Semantic Scholar",
      "interactions": "STRING",
      "clinical": "Open Targets",
      "drugs": "DGIdb + PubChem + ChEMBL",
      "ai": "GPT-4o-mini",
      "hypothesisEngine": "GaiaLab AI (Graph Neural Networks + Probabilistic Reasoning)"
    },
    "dataAvailability": {
      "literature": {
        "pubmed": true,
        "semanticScholar": true
      },
      "pathways": {
        "kegg": true,
        "reactome": true
      },
      "interactions": {
        "string": true,
        "biogrid": false
      },
      "clinical": {
        "openTargets": true,
        "disgenet": false,
        "gwasCatalog": true
      },
      "drugs": {
        "chembl": true,
        "drugbank": false,
        "drugbankFallback": false,
        "dgidb": true,
        "pubchem": true
      }
    },
    "databaseStats": {
      "totalDatabases": 16,
      "availableDatabases": [
        "Ensembl",
        "ClinVar",
        "UniProt",
        "Gene Ontology",
        "KEGG",
        "Reactome v95",
        "PubMed",
        "Semantic Scholar",
        "STRING",
        "Open Targets",
        "DGIdb",
        "PubChem",
        "ChEMBL"
      ],
      "availableCount": 13,
      "bioactiveCompounds": "2.4M+",
      "databases": [
        "UniProt",
        "KEGG",
        "Reactome",
        "PubMed",
        "STRING",
        "Open Targets",
        "BioGRID",
        "Gene Ontology",
        "Ensembl",
        "GWAS Catalog",
        "DisGeNET",
        "ClinVar",
        "ChEMBL",
        "PubChem",
        "DrugBank",
        "Semantic Scholar"
      ]
    },
    "snapshot": null,
    "disclaimer": "AI-generated insights for research purposes. Requires expert validation. Not medical advice.",
    "cacheStats": {
      "cached": false,
      "timestamp": 1768511846234,
      "tier": "fresh",
      "hitRate": 0
    }
  },
  "modelConfig": {
    "aiModelUsed": "GPT-4o-mini",
    "modelTimeoutMs": 90000,
    "providers": {
      "openai": true,
      "deepseek": true,
      "gemini": false,
      "anthropic": true
    },
    "modelIds": {
      "openai": "gpt-4o-mini",
      "deepseek": "deepseek-chat",
      "gemini": "gemini-2.0-flash-exp",
      "anthropic": "claude-3-5-sonnet-latest"
    },
    "includeDrugs": true
  },
  "versions": {
    "app": "0.1.0",
    "node": "v22.18.0"
  },
  "signature": "e75cbdfb2da7"
}